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C. Aims and outline of  the thesis 
This thesis aims to gain a better understanding of  the clinical conditions and safety of  
induction and switch to buprenorphine-naloxone in opioid dependent patients from another 
medication, such as buprenorphine, methadone and levo-methadone, or active street heroin 
use. To answer the aims of  this thesis, data from the nationwide, non-interventional, 
observational post-authorization safety study (PASS) with buprenorphine-naloxone in routine 
care with a 12-month observation period was used (described in chapter E.3.). 
The aims of  the thesis were:  
- to evaluate the results from the PASS in patients pre-treated with buprenorphine, 
methadone, levo-methadone or another maintenance drug after 12 months of  treatment 
with buprenorphine-naloxone under real-life conditions 
- to describe retention rates and safety of  patients in treatment with buprenorphine-naloxone 
in routine care 
- to assess the circumstances of  the switch to buprenorphine-naloxone such as dosing, mode 
of  prescription and subjective effects 
- to examine effectiveness, tolerance and acceptance of  opioid dependence treatment with 
buprenorphine-naloxone 
- to evaluate the predictive value of  the first four weeks of  opioid dependence treatment with 
buprenorphine-naloxone in routine care with regard to positive and negative treatment 
outcomes 
- to assess the risk for liver enzyme elevation in patients in opioid-dependence treatment with 
buprenorphine-naloxone in routine care 
The thesis is based on four chapters: 
- Introduction (chapter E)  
- Primary analysis of  the results from the 12-month nationwide non-interventional safety 
study on the medication assisted treatment of  opioid dependence with buprenorphine-
naloxone in routine care in Germany (chapter F) 
- Analysis of  the first four weeks in the treatment of  opioid-dependence after induction or 
switch to buprenorphine-naloxone and its predictive value for the treatment outcome after 
12 months of  observation (chapter G)  
- Analysis of  the development of  liver enzymes over 12 months of  treatment of  opioid-
dependence with buprenorphine-naloxone (chapter H) 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D. Introduction 
D.1. Opioid use disorder 
Opioid use disorder (OUD) is a major health and social issue worldwide [1] and can lead to 
significant somatic and psychiatric complications. In the International Classification of  
Diseases (ICD-10) the dependence syndrome is described as a physiological, behavioral and 
cognitive phenomenon. The addicted person grants the drug use a higher priority in life than 
anything else and feels a strong desire to acquire and consume the drug despite the 
knowledge of  its harmful consequences [2, 3]. Approximately 1.3 million persons are high-
risk opioid (mis-)users in Europe. Most of  them are using street heroin; a minority misuses 
prescription opioids such as methadone, buprenorphine or fentanyl [4]. In the beginning the 
use of  opioids might cause feelings of  drowsiness, euphoria and relieve of  distress, but 
repeated use will rapidly lead to a physical adaptation to the effects of  the drug and to 
uncontrollable drug consumption [5, 6]. The drug abusing person 1) will experience a 
physiological state of  adaptation to the drug and needs to increase the drug dose and/or 
reduce intervals between drug consumption because of  its loss of  effectiveness (tolerance), 
2)  will have withdrawal symptoms when the drug use is abruptly stopped (physical 
dependence) and 3) will be developing behavioral patterns of  compulsive drug procurement 
and use (addiction) [5, 7, 8]. At some point the opioid is no longer consumed as positive 
reinforcer to produce euphoria or relieve distress, but to prevent withdrawal symptoms and 
dysphoria [5]. Long-term exposure to opioids alters the neurological system of  the reward 
mechanism; it becomes highly sensitive to both the drug effects and the stimuli around the 
drug-use and causes constant need (craving) for the drug even when no withdrawal symptoms 
are present [5]. Approximately half  of  the opioid dependent persons will continue (mis-)using 
the opioid for the rest of  their life with intermittent periods of  treatment, imprisonment, 
abstinence and relapse [2] with high overdose and mortality risks [9]. Therefore opioid 
addiction is considered a chronic recurring medical disease [5] with a high risk for a fatal 
outcome. 
D.1.1. Opiate vs. opioid 
Opiate is the term for all natural psychoactive substances based on raw opium obtained from 
the seed capsule of  the plant papaver somniferum (breadseed or opium poppy) which mainly 
contains morphine and codeine [10, 11]. Opiates have a long history of  medicinal use and 
non-medicinal abuse worldwide [10].  
Opioid is the term for all half  synthetic substances based on opium/morphine such as heroin 
(diacetylmorphine) or thebain such as buprenorphine as well as all fully synthetic substances 
such as methadone and levo-methadone which have similar pharmacological effects as opiates 
[10-12]. Opioids were developed to produce more potent analgesics and reduce abuse liability 
of  opiates [10]. Until now there is no opioid which has not been abused at some point. 
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Both opiates and opioids have a high addictive potential and will eventually lead to tolerance 
and withdrawal symptoms [11]. The most prominent route of  application is intravenous (iv), 
which is also the highest risk factor for severe morbidity and premature mortality [2]. 
Throughout the literature the terms opioids and opiates are often used interchangeable 
(sometimes even misclassified as synonyms) with a more prominent use of  the term opioid for 
both groups. In this thesis the term opioid is used for harmonization reason. 
D.1.2. Agonist vs. antagonist 
The term opioid agonist is used for substances (body’s own or external) which have an affinity 
with opioid receptors and activate their function. These substances are further distinguished 
into full and partial agonists. An increased dose of  a full agonist increases the effect of  the 
substance and the activity of  the receptors. Partial agonists trigger a limited reaction at the 
receptor even at high dosages. Partial agonists have a partial antagonistic effect because they 
block the opioid receptors and reduce the potency of  a full agonist. Partial agonists can also 
cause precipitated withdrawal symptoms because they supersede the full agonist from the 
receptor since they usually have a higher affinity to the same receptor (i.e. buprenorphine). 
[see 13] 
The term opioid antagonist is used for substances (body’s own or external) which have an 
affinity with the opioid receptors and block them, but do not activate their receptor function. 
Competitive antagonists are competing with the agonists for the same bonding spot on the 
receptor and block the binding potential for the agonist. Non-competitive antagonists bind to 
another spot at the same receptor and inhibit the receptor function. Agonists can still bind to 
the receptor but its maximal effects are always reduced due to the presence of  the non-
competitive antagonist. [see 13] 
D.1.3. Opioid receptors 
Opioid receptors are molecules on the surface of  the cells and in the human body different 
types of  opioid receptors exist [7]. Mainly μ (mu), δ (delta) and κ (kappa) receptors were found 
to be relevant for opioid drug use disorders [10, 14]; all of  them can be further divided into 
subtypes - μ1 and μ2, δ1 and δ2, κ1, κ2 and κ3 [10, 15].  
Especially the μ receptor is important for the analgesic and addictive effects of  opioids and 
the mediation of  drug reinforcement. According to the review from Contet and colleagues 
[16] this receptor plays a major role in the processes for continued drug use and craving. It 
provides a high affinity with opioids with abuse potential [10, 17] and is relevant for pain 
regulation and sensorimotor integration [14]. Moskowitz and colleagues found that μ1 is 
responsible for the analgesic effects and μ2 for respiratory depressant effect [18].  
The κ receptor plays a major role in the aversive effects of  opioids and seems to be 
responsible for the negative mediation of  behavioral response to opioids and dysphoria [10, 
19]. Certain agonists/antagonists can attenuate the rewarding effects of  opioids when 
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attaching to the κ receptor [19]. Hence this receptor is also very important for the 
development of  medications for opioid drug dependence treatment.  
The δ receptor seems to have an important role in the rewarding effect of  opioids as well as in 
the development of  opioid tolerance and dependence [20]. The activation of  this receptor 
can reduce pain and improve emotional conditions [21]. Yet this receptor has not been in the 
main focus for studies concerning OUD [21]. While early animal studies with selective δ 
receptor antagonists provided evidence for reduced development of  opioid tolerance and 
dependence, Pradhan and colleagues [21] noted that its usefulness for opioid drug 
dependence treatment is still not entirely clear.  
D.1.4. Adverse effects and long-term consequences of  opioid addiction 
In the long-term untreated OUD leads to severe morbidity and increased premature 
mortality risk [2, 4, 22-26]. 
Mortality 
According to the Drug and Addiction Report [27] in 2010 in total 1,237 persons died from a 
drug overdose in Germany. Most of  those deaths (approximately 70%) were attributed to an 
overdose of  heroin alone or in combination with another drug. In approximately 14% of  the 
death cases, evidence of  an overdose by a drug used for medication assisted treatment for 
opioid dependence such as methadone, levo-methadone or buprenorphine alone or in 
combination with another illicit drug was found. 214 persons died from the long-term effects 
of  the high risk use of  illicit drugs. In the following two years 2011 and 2012 the number of  
drug-related deaths decreased in Germany. However, since 2013 death cases have been 
increasing continuously and reached the level of  2010 again in 2015 [4]. According to the 
latest report by the European Monitoring Center for Drugs and Drug Addiction [4] opioids 
were involved in 80% of  the drug-related death cases with known toxicology. The Drug and 
Addiction Report from 2017 [11] had to declare another 9% increase of  drug-related deaths 
in 2016. This means that the number of  drug related deaths reached the level of  2009. Most 
of  those deaths in 2016 were attributed to opioids alone or in combination with other 
substances [11]. 
The reasons for the continued increase of  drug-related deaths in Germany are not entirely 
clear. The „Drug Commissioner of  the Federal Government“ in Germany pointed to the 
increase of  polyvalent intoxications with drugs other than opioids such as cocaine (+78% 
compared to 2015), methamphetamines i.e. Crystal Meth (+2 deaths compared to 2015) and 
new psychoactive substances including synthetic cannabinoids (+51% compared to 2015) 
[11]. For the increased number of  opioid-related deaths, the „Drug Commissioner“ did not 
provide an official explanation in the Drug and Addiction Report from 2017 apart from a 
slight increase of  deaths because of  intoxications with fentanyl (+9% compared to 2015). 
During the press conference in 2017, shortly after the release of  the Drug and Addiction 
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Report, the speakers emphasized that an increased quality of  the drugs in combination with 
decreased prices were part of  the root cause [28].  
Virological and other Infections 
Because of  high-risk behavior (e.g. needle sharing and unprotected sex with different partners) 
and unstable social conditions (e.g. homelessness and imprisonment) the risk for virological 
and other infections is elevated in drug dependent persons [29]. Among patients with iv drug 
use the prevalence of  an infection with the hepatitis C virus (HCV) is more than 50% and of  
the human immunodeficiency virus (HIV) is below 5% in Europe [29]. Results from the 
national study DRUCK, conducted by the Robert Koch Institute (RKI) from 2012 until 2016 
in Germany, showed a high prevalence of  up to 75% for HCV and up to 9% of  HIV in drug 
dependent persons with iv drug use [30]. Older age (≥35) and longer history of  iv drug use 
contributes to an increased risk for viral infections [29, 30]. Alcohol abuse or even 
dependence worsens the condition in chronic HCV infections resulting in cirrhosis, liver 
cancer and premature death [29]. Chronic use of  opioids generally has an immuno-
suppressive effect which can also lead to an increased vulnerability to infections, 
inflammations and cancer diseases. In persons with iv drug use the risk for severe bacterial 
infections such as tetanus, botulism and streptococcus is highly elevated [29]. 
Psychiatric Disorders 
Psychiatric disorders are found to be associated with elevated risk for drug abuse and 
addiction. Especially schizophrenia, bipolar disorders, depression and attention deficit 
hyperactivity disorder (ADHD) are conditioning factors for drug abuse [5]. Post-traumatic 
stress disorders (PTSD) were also found to be a high risk factor for drug abuse and 
dependence [31-33].  
Long-term abuse of  opioids and its coherent life-style leads to an increased risk for comorbid 
psychiatric disorders such as anxiety, depression and PTSD as well as cognitive and 
neurological deficits [1, 22, 33-35].  
D.2. Treatment of  opioid use disorder 
There are different strategies for the treatment of  OUD: 1) withdrawal and detoxification, 
2) medication assisted treatment with agonists, partial agonists and antagonists and 3) psycho-
social therapy. Psychosocial therapy is an important approach in the treatment of  OUD, 
either as a standalone program or in combination with medication assisted treatment [7], but 
will not be further discussed herein. This thesis is focused on medication assisted treatment. 
In Europe approximately 630,000 persons classified as high-risk opioid misusers are currently 
in therapy; most of  them in medication assisted treatment with methadone, levo-methadone 
or buprenorphine products [4]. In general being in treatment seems to reduce the risk for 
hospital attendances, morbidity and mortality. In opioid dependent patients who are out of  
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treatment all cause mortality risk is up to 3.5 times and overdose mortality risk is up to 4.9 
times higher compared to patients who are still in treatment [2, 9, 36, 37]. The risk for 
mortality is particularly high during the first four weeks after leaving treatment [9, 36, 38, 39]. 
In their retrospective analysis of  ambulance service records over a four year period in 
Australia, Nielsen and colleagues [40] found that methadone or buprenorphine was involved 
in only 5 cases compared to monthly up to 460 heroin-related cases. 
D.2.1. Withdrawal and detoxification 
Opioid withdrawal and detoxification is used to bring a patient from opioid dependence to an 
opioid free state [41] within a short period of  time (24 hours to 2 weeks). The medication 
assisted opioid withdrawal treatment is presently the standard treatment for detoxification 
[42] and can be done as traditional or rapid/ultra-rapid detoxification using agonistic opioid 
substitute medicine, such as methadone or buprenorphine, non-opioid medicine, such as 
clonidine and lofexidine, opioid antagonistic medicine, such as naloxone and naltrexone, or a 
combination of  the above mentioned medications [43-45]. The successful completion of  
opioid detoxification is a requirement for the start of  a weaning off  treatment with an opioid 
antagonist [42].  
During the traditional detoxification from heroin with an opioid substitute, the dosage of  the 
substitute, such as methadone or buprenorphine products, will be gradually tapered during 
several days or weeks until the patient no longer requires any substitute medication to prevent 
withdrawal symptoms and can then be transferred to opioid antagonist treatment [42, 46, 
47]. The duration of  this type of  detoxification treatment depends on the start dosage of  the 
substitute medication needed to replace the abused opioid [42]. Detoxification with 
methadone is effective to alleviate withdrawal symptoms. However, the post-detoxification 
treatment with an opioid antagonist would require up to one week of  methadone abstinence 
to avoid precipitated withdrawal and the relapse rate is very high [43]. Detoxification with 
buprenorphine is also safe and well tolerated; withdrawal symptoms are resolved faster 
compared to methadone [45, 47, 48]. The non-opioid approach of  the traditional 
detoxification treatment is conducted by using ⍺2-adrenergic agonists, such as clonidine and 
lofexidine, to decrease overactivity of  the cyclic adenosine monophosphate (AMP) system in 
noradrenergic neurons and to reduce opioid withdrawal symptoms [44]. The medication is 
tapered over a period of  5-10 days until it can be completely stopped [43, 44]. In their 
outpatient study McCann and colleagues found that clonidine detoxification was more 
successful for patients whose most recently used drug was any opioid other than heroin, who 
did not inject the opioid and waited longer after the last dose of  their drug of  choice before 
starting detoxification treatment [43]. Compared with the opioid detoxification with ⍺2-
adrenergic agonists alone the combination with an opioid antagonist such as naltrexone seems 
to be more successful and the resolution of  opioid withdrawal symptoms is more rapid 
[49-51]. A different approach for a successful detoxification is presented by Kosten and 
O’Connor. They recommended for an optimal outpatient detoxification to start with 
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buprenorphine, tapering the dose until discontinuation, and switch to lofexidine or clonidine 
for up to 5 days [44].  
The rapid and the ultra-rapid detoxifications are usually done with a combination of  ⍺2-
adrenergic agonists and opioid antagonists. In both approaches precipitated withdrawal with 
an opioid antagonist is used to shorten the time needed for withdrawal [45]. During the rapid 
opioid detoxification a high dose of  clonidine or lofexidine is decreased while the dose of  
naltrexone or naloxone is increased within 2 to 6 days until no precipitated withdrawal is 
experienced and the patient can be maintained on naltrexone alone [42, 44, 45, 52]. For the 
ultra-rapid detoxification the patient is in anesthesia or heavy sedation and receives an opioid 
antagonist such as naloxone while in intensive care for one day [42, 44, 45]. As post-
procedures vary widely internationally [45], in Germany, after retrieval from narcosis or 
sedation, the patient would receive further opioid antagonist treatment and medication for 
withdrawal symptoms for about a week before being discharged from the hospital [42]. As 
Scherbaum and colleagues [42] concluded, ultra-rapid detoxification is only applicable for 
non-polyvalent opioid dependent persons. Despite 90-100% successful completion of  this 
detoxification treatment, the long-term success of  this approach is questionable [42, 45] and 
there is a high risk for clinical complications as well as mortality [45, 46]. Another ultra-rapid 
approach was presented by Resnick and colleagues. Patients were given repeated injections of  
the opioid antagonist naloxone until withdrawal symptoms were no longer induced and the 
patient was transferred to naltrexone maintenance within 48 hours [53]. 
During opioid detoxification, withdrawal symptoms (e.g. insomnia, muscle cramps, pain, 
diarrhea, nausea, vomiting, flu-like symptoms) can be treated with mitigating medications, 
such as benzodiazepines, nonsteroidal anti-inflammatory drugs or prochlorperazine, as they 
arise [41, 42, 45].  
Almost all authors concluded that long-term success of  any type of  opioid detoxification is 
rather doubtful. Short-term detoxification programs alone are not sufficient in preventing 
deaths and achieving long-term abstinence [26, 54]. After detoxification from the drug and 
dissipation of  withdrawal symptoms, drug addiction does not end [55] as the underlying 
chronic opioid use disorder is not addressed by detoxification treatment [55]. Therefore 
detoxification should only be considered a first step in a long-term substance abuse treatment 
process [46, 55]. 
D.2.2. Medication assisted treatment 
Medication assisted treatment is the most frequent therapy for opioid dependent patients [4]. 
The main goals are to keep the patient alive, stabilize the patient, prevent withdrawal 
symptoms, reduce high-risk and health threatening behavior (incl. drug-related crime), enable 
social re-integration and treatment of  co-morbid diseases [1, 24, 56]; thus, prevent or at least 
reduce drug-related deaths from overdose and drug-use related physical diseases. The drug 
dependent person is given the chance to reclaim control over his or her life [4, 57].  
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Medication assisted treatment with maintenance drugs consists of  three phases: induction, 
stabilization and maintenance [4, 6]. The induction phase usually lasts up to one week. 
During this phase the treating physician will find the minimum dose of  the maintenance drug 
at which the patient no longer experiences withdrawal symptoms as well as uncontrollable 
craving for opioids and concomitant drug use markedly decreases [7]. The stabilization phase 
usually lasts one to two month(s). The patient is stabilized in the routine of  drug dependence 
treatment and opioid use further decreases, which shows in an increasing number of  negative 
urine drug screenings [7]. The maintenance phase is the longest period in drug dependence 
treatment and can last life-long. The patient receives a stable dose of  the maintenance drug 
and is ready for addressing co-morbid diseases as well as psychosocial, family, employment 
and financial issues [7]. 
The first four weeks in medication assisted treatment seem to be important for course and 
outcome of  opioid dependence treatment. Some studies reported the highest drop-out rates 
in the first weeks of  therapy [58, 59] especially in patients induced to buprenorphine [60, 61] 
and patients with positive urine drug screenings for opioids [35, 62]. A high mortality risk 
after treatment onset has also been reported particularly for patients induced to methadone 
[9]. A patient is more likely to terminate treatment within the first three months if  tested 
positive for opioids and other illicit drugs [63]. The odds for a successful medication assisted 
treatment, including complete abstinence, increase with a longer duration of  the therapy [59, 
64, 65]. Therefore, it is important to monitor the initial response of  patients closely after 
treatment onset [35] and keep them in the treatment beyond the first four weeks. 
Medication assisted treatment with antagonists (e.g. naltrexone) is usually done as weaning off  
treatment after a successful detoxification [42, 66]. Opioid antagonists block the effects of  
other opioids such as heroin [67]. A purely antagonist treatment for opioid dependent persons 
is limited because of  poor compliance of  the patient to the treatment and high drop-out rates 
[67-69] due to the lack of  agonistic effects and continued experience of  craving for opioids 
[7]. The risk for overdose is also increased in case of  a relapse to opioid use [7]. Studies 
showed significantly more successful treatment results when the medication assisted treatment 
with an antagonist is combined with intensive psychiatric counseling or even psychotherapy 
[68-70]. Recent trials with sustained-release naltrexone showed promising results concerning 
medication compliance compared to the oral medication [71], but to date the data is not 
sufficient to conclude on the effectiveness for opioid dependence treatment [67]. 
KUMULATIVE DISSERTATION S. M. APELT, DIPL.-PSYCH "19
D.2.2.1. Medications for opioid dependence treatment 
Methadone 
 
Fig 1: Structural formula of  d/l-methadone C21H27NO [72] 
Methadone or d/l-methadone is a long acting full µ receptor agonist and a fully synthetic 
derivate of  morphine. Methadone consists of  the active R(-)enantiomer levo-methadone and 
the inactive S(+)enantiomer dextro-methadone [8, 72]. In drug dependence treatment the 
medication is administered orally as a solution. To effectively suppress withdrawal symptoms, 
methadone must be administered on a daily basis [73, 74]. After oral administration 
methadone is detectable in the blood plasma after 30 minutes and reaches its peak at about 4 
hours [8]. 90% of  the drug is bound to plasma protein with a half-life of  approximately 15 to 
40 hours [8, 72]. 
Methadone has a high ratio of  oral-to-parenteral potency which reflects the low first-pass 
metabolism in the liver [8]. It produces adverse effects such as respiratory depression, nausea, 
dizziness and hypotension [72]. As most opioids methadone is metabolized by the cytochrome 
P450 3A4 system [72, 73]. Therefore the dose will need to be adjusted in patients undergoing 
medication treatment for a hepatic disease (e.g. HCV) or HIV as changes in bioavailability 
and cumulative effects may occur after oral administration of  methadone [8, 73]. 
When inducting a patient to methadone in medication assisted treatment of  opioid 
dependence, it is recommended the patient is no longer intoxicated and does show 
withdrawal symptoms. The initial dose of  maximum 30 mg and a maximum dose of  40 mg 
on the first day as well as a maintenance dose of  60 to 120 mg per day is recommended. [75]. 
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Because methadone is a full opioid agonist with a complex pharmacokinetic profile it has high 
potential for misuse and diversion. 
Levo-Methadone  
 
Fig 2: Structural formula of  levo-methadone C21H27NO [72] 
Levo-methadone is a long acting full µ receptor agonist and fully synthetic derivate of  
morphine. Levo-methadone consists of  the active R(-)enantiomer of  d/l-methadone, from 
which the S(+)enantiomer dextro-methadone is removed. Levo-methadone is approximately 
twice as effective as d/l-methadone and dosing needs to be considered accordingly. As with 
methadone it is administered orally as solution and it produces adverse effects such as 
respiratory depression, nausea, dizziness and hypotension [76]. Plasma bonding, half-life and 
metabolism are similar to d/l-methadone. The induction dose on should not exceed 20 mg 
and for maintenance a daily dose between 30 to 60 mg is recommended.[77] 
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Buprenorphine 
 
Fig 3: Structural formula of  buprenorphine C29H42ClNO4 [72] 
Buprenorphine is a semisynthetic partial µ receptor agonist and κ antagonist derivate of  
thebain and is 20 to 50 times more potent than morphine [7, 8, 78]. For opioid dependence 
treatment buprenorphine is administered sublingually [7]. Due to its low intrinsic activity at 
the µ receptor even with full saturation of  the receptor system and its dose related ceiling 
effects on subjective and physiological measures (e.g. euphoric and respiratory depressant 
effects) [7, 78], buprenorphine has a high safety profile when used as prescribed. After 
sublingual administration buprenorphine reaches its peak at about 1 to 2 hours [8]. In 
addition buprenorphine can be administered less than daily (alternate dosing every 2 or 3 
days) because of  its slow dissociation from the µ receptor and therefore, long lasting effects 
with higher doses without increased risk [74, 78-81]. Buprenorphine attenuates the effects of  
other opioids due to its strong bonding to the µ receptor [82, 83] and can be safely used for 
rapid tapering (7 days) and detoxification [84]. 96% of  buprenorphine is bound to the plasma 
protein with a half-life of  about 3 hours, but because of  the slow dissociation from the 
µ  receptor, plasma levels of  buprenorphine may not be reflected in the clinical effects [8]. 
Buprenorphine is extensively metabolized in the liver to norbuprenorphine by the 
cytochrome P450 3A4 system [85]. Other medications also interacting with the same system 
may enhance or decrease effects of  buprenorphine and should be used with caution [7]. 
Elevated liver enzyme levels for aspartate transaminase (AST) and alanine transaminase 
(ALT) have been reported during treatment with buprenorphine, especially in patients with a 
history of  hepatitis [86], and when buprenorphine was misused intravenously or in very high 
doses [87]. Buprenorphine produces adverse effects such as nausea, dizziness and hypotension 
but not as extensively as a full agonist [7]. 
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When inducting a patient to buprenorphine, the patient needs to be in slight withdrawal from 
the full agonist to prevent precipitated withdrawal [6]. As a partial agonist on the µ receptor, 
buprenorphine is also acting like a partial antagonist on the same receptor by superseding the 
full agonist. For induction to buprenorphine the patient should receive the recommended 
minimum daily dose and for maintenance a daily dose of  16 mg (range 4 to 24 mg) [6]. 
Buprenorphine-Naloxone 
 
Fig 4: Structural formula of  buprenorphine naloxone mixture C48H62N2O8 [72] 
Buprenorphine-naloxone is a combination of  buprenorphine and the short-acting antagonist 
naloxone in a 4:1 ratio [88-90]. This combination was developed to minimize the diversion 
and potential misuse of  the medication [88, 91]. The antagonist naloxone has a very low 
bioavailability (<10%) when administered sublingually [91]. If  buprenorphine-naloxone is 
administered intravenous, it produces antagonistic and bad drug effects (i.e. opioid 
withdrawal) [89, 91] comparable to the use of  naloxone alone. Buprenorphine-naloxone is 
preferable in drug dependence treatment with buprenorphine, since the antagonist naloxone 
prevents patients from dissolving the tablet for iv use [6]. Take home prescription could be 
granted more often because of  the reduced risk for diversion and misuse [92] and could 
increase treatment compliance also in combination with the possibility of  alternate dosing 
[92]. Plasma bonding, half-life, metabolism and side effects are similar to buprenorphine 
mono-compound. 
In Europe buprenorphine-naloxone is only available as sublingual tablet for medication 
assisted treatment of  opioid dependence [90]. Outside of  Europe this medication is also 
approved as sublingual film [93]. The official product description recommends the same daily 
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dose as with buprenorphine and warns that due to the naloxone portion, the medication 
should not be used in patients with severe liver problems [90]. 
Other maintenance drugs 
Codeine is a short-acting natural full agonistic content of  morphine/opium and dihydro-
codeine (DHC) is a short-acting semisynthetic full agonistic derivate of  morphine. Both 
substances require more than one daily dose to prevent withdrawal symptoms due to a 
„weak“ affinity with the µ receptor, a short half-life of  3-4 hours and a duration of  action of  
approximately 6 hours [94-96]. They are metabolized through the cytochrome P450 enzyme 
CYP2D6 to several compounds including the active metabolite (dihydro-)morphine, which 
has a 60 times higher affinity with the µ receptor as its parent compound [97]. DHC has a 
higher portion of  the metabolite dihydromorphine and is therefore 3-fold stronger than 
codeine [96]. Due to the genetic polymorphism of  CYP2D6 there is an individual diversity in 
metabolic profiles, and pharmacological affects vary depending on the speed of  codeine/
DHC metabolization [97]. Adverse effects are similar to methadone with more frequent 
obstipation and upper abdomen ailment [96]. 
Diamorphine/diacetylmorphine (DAM) is a half-synthetic full-agonistic diacetyl derivate of  
morphine [72, 94] with a high intrinsic activity at the µ-receptor, especially its metabolite 6-
monoacetylmorphine (6-MAM) which is rapidly hydrolyzed after administration of  DAM 
[72, 98, 99]. Because of  the short half-life and a duration of  action of  no more than 4 to 5 
hours, the drug needs to be applied at least three times a day [96]. The most common adverse 
effects are sedation, nausea and vomiting, constipation and sweating including respiratory 
depression as the most serious adverse effect [72, 96]. 
D.2.2.2. Medication assisted treatment in Germany 
Since July 2002 all physicians working in addiction medicine are obligated to register each 
patient receiving any medication assisted treatment for opioid dependence in the 
Substitutionsregister [11]. While the number of  registered opioid dependent patients in 
medication assisted treatment continuously increased until 2010 (52,700 in 2003 to 77,400), it 
remained practically stable until 2015 (77,500) and only slightly increased in 2016 to 78,500 
[11].  
Until 2002 the majority of  opioid dependent patients in medication assisted treatment 
received methadone, which was first introduced for maintenance treatment in Germany in 
1987 [100]. Only in Germany methadone is available in two forms for opioid dependence 
treatment: d/l-methadone and levo-methadone, also called polamidon [100]. Levo-
methadone prescriptions for opioid dependence treatment increased from >16% in 2002 to 
33% in 2016. After market approval in 2002 the proportion of  patients treated with 
buprenorphine increased from <10% to >23% in 2016 and includes the combination 
product buprenorphine-naloxone marketed in Germany in 2006. Codeine/DHC were used 
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as substitute drugs by heroin addicts since the 1960s [97] and since the 1970s DHC was 
prescribed as oral solution to a large number of  opioid dependent persons due to the strict 
narcotic regulations for methadone maintenance treatment in Germany at that time [94, 100, 
101]. In 1998 the prescription of  codeine/DHC had been restricted by law to only 
exceptional medical cases, e.g. patients intolerant to methadone, because of  an increased 
number of  „gray substitution“ (patients did not have to be notified to local health authorities) 
and an increased number of  codeine-related deaths [94]. Prescriptions decreased from 2% in 
2002 to 0.3% in 2016 [11]. Since 2010 diamorphine-assisted treatment is available as second-
line treatment for a small sub-group of  „difficult-to-treat“ opioid dependent patients for 
whom conventional treatments were not successful [102, 103]. The prescriptions for this last 
option for medication assisted treatment increased from 0.3% in 2010 to 1% in 2016. [11, 
104, 105] . 
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D.3. Post-authorization safety study (PASS) with buprenorphine-naloxone 
After market approval for buprenorphine-naloxone (Suboxone®) in Europe a nationwide non-
interventional, post-authorization safety study (PASS) was conducted to evaluate the safety 
and effectiveness of  the medication on a large and representative sample of  patients in office 
based opioid drug dependence treatment in Germany. The study was part of  the Risk-
Management-Plan (RMP) for buprenorphine-naloxone and a commitment to the European 
Medicine Agency (EMA). The 12-month PASS was conducted from 2008 to 2010 and 
included 69 sites and 384 opioid dependent patients (see Figure 4). 
Methods and design of  the study are extensively described in paper I provided in chapter F. 
 
Figure 4: Design of  the PASS with buprenorphine-naloxone (paper I) 
The majority of  the participating physicians were male (83%) and on average 53.4 years of  
age (SD 7.3, 40-70). Almost 60% of  the physicians were working in cities with >100,000 
inhabitants, 10% with >50,000 inhabitants, 24% with >10,000 inhabitants and 7% in towns 
with <10,000 inhabitants. More than half  of  the physicians (54%) were general practitioners, 
followed by psychiatrists (19%), internists (15%), medical practitioners (10%) and other fields 
of  specialization (2%). There were no gynecologists or hepatologists participating in the study. 
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The participating physicians were working in the field of  dependence treatment on average 
for 14 years (SD 6.2, 1-30). Almost 80% of  the participating physicians were working office-
based in an individual practice (40%), group practice (23%) or shared practice (16%). One 
physician was working in a drug help facility, one was working in a clinic and two physicians 
were working in health care centers. The majority of  the physicians (84%) were treating >40 
opioid dependent patients per day, 14% were treating >10 patients per day and only 2% were 
treating <10 patients per day. Opioid dependent patients could either receive their 
medication directly at the site of  their treating physician (77%) or at a pharmacy (30%). 
Virological tests for hepatitis A, B, C and HIV were done on a regular basis by >70% of  the 
physicians. For the treatment of  virological infections, patients were transferred to a 
specialized facility by >65% of  the physicians. Concomitant use of  illicit drugs was monitored 
by interview mostly on a weekly basis (63%), by urine drug screening weekly and monthly 
(34% and 49%, respectively), by urine laboratory test monthly or seldom (32% and 25%, 
respectively) and by blood tests seldom or never (58% and 24%, respectively). 46% of  the 
participating physicians offered an accompanying psychosocial treatment in their practice. 
86% of  physicians used a drug help facility and 25% a psychiatrist or psychologist for 
additional psychosocial treatment.  
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E. Primary analysis of  the results from the 12-month nation-
wide non-interventional safety study on the treatment of  
opioid dependence with buprenorphine-naloxone in 
routine care in Germany (Paper I) 
___________________________________________________________________________
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Sabine M. Apelt, Norbert Scherbaum, Jörg Gölz, Markus 
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This  article  provides  a  detailed  description  of  the  methods  and  design  of  the  non-
interventional post-authorization safety study with buprenorphine-naloxone. It describes the 
characteristics of the study population and answers the primary and secondary objectives of 
the study. 
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 Safety, Eff ectiveness and Tolerance of Buprenorphine-
Naloxone in the Treatment of Opioid Dependence: 
Results from a Nationwide Non-Interventional Study 
in Routine Care
 One of the reasons for the lowest number of 
drug-related deaths in the past 10 years  [ 5 ] is 
opioid maintenance treatment which is an estab-
lished and well-studied approach in opioid 
dependence and recommended by current treat-
ment guidelines worldwide  [ 6 – 9 ] . The main 
goals of opioid drug dependence treatment are 
risk and harm reduction, social reintegration, 
and interruption of the vicious circle of drug use 
and procurement crime. Furthermore the ther-
apy aims to establish best possible conditions for 
the treatment of concomitant diseases  [ 10 ] . 
Although abstinence is no longer the only pri-
mary goal, the long-term target of opioid drug 
dependence treatment is to support the patients 
to stop using drugs entirely  [ 10 ] .
 In 2010 more than 77 000 of approximately 
200 000 opioid-dependent patients in Germany 
 Introduction
 ▼
 Opioid dependence is a major health and social 
issue  [ 1 ,  2 ] and is associated with an excess rate 
of somatic and psychiatric complications includ-
ing HIV, hepatitis, depression, suicidality and 
antisocial behaviour  [ 1 ,  3 ,  4 ] . Approximately 
200 000 persons in Germany have a risky use of 
illicit substances, excluding cannabis use  [ 5 ] . 
Although the number of drug-related deaths con-
tinues to decrease still 1 237 persons died in 
2010 because of drug use, most of them because 
of heroin overdose (42.8 %), 12.5 % of the deaths 
were related to methadone/levo-methadone 
alone or in combination with other drugs and 
0.5 % were related to buprenorphine alone or in 
combination with other drugs  [ 5 ] .
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 Abstract
 ▼
 Introduction:  Buprenorphine is well known in 
the treatment of opioid dependence. Despite a 
high safety profi le and good tolerance buprenor-
phine has been subject to misuse and diversion. 
To reduce misuse the antagonist naloxone was 
added and the 4:1 combination of buprenor-
phine-naloxone was launched in Germany in 
March 2007. On the basis of the results from 
international clinical trials a non-interventional 
study was conducted to gather data on safety, 
eff ectiveness, retention and acceptability of 
buprenorphine-naloxone in the treatment of 
opioid dependent patients in routine care.
 Methods:  A nationwide multicentre 12-month 
prospective, non-interventional, post-marketing, 
surveillance study was carried out with 12 
assessment points in N = 384 opioid dependent 
patients currently in maintenance treatment 
from N = 69 general practitioners, clinics and out-
patient clinics in Germany.
 Results:  N = 337 data sets were eligible for anal-
ysis. The rates of patients with serious and non-
serious adverse events were low with 1.2 % and 
17.5 %, respectively. No deaths occurred during 
the observational period and only one hospitali-
zation was documented. Concomitant drug use 
decreased for all illicit substances. Mental health 
and quality of life measured with standardized 
self-assessment questionnaires improved signifi -
cantly. The 12-month retention rate was 57.1 %. 
Of the n = 181 patients still in treatment at the 
end of the observation period, 96.7 % continued 
treatment with buprenorphine-naloxone.
 Conclusion:  The fi ndings of the non-interven-
tional study indicate high eff ectiveness and 
safety of buprenorphine-naloxone in the treat-
ment of opioid dependence. The medication was 
well accepted by opioid dependent patients in 
long-term substitution treatment with substan-
tial reductions of concomitant drug use and 
measurable improvement in quality of life.
Affi  liations Affi  liation addresses are listed at the end of the article
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were registered as currently in maintenance treatment with d/l-
methadone (58 %), levo-methadone (23 %), buprenorphine (19 %) 
and other substitution drugs including diamorphine (0.3 %) 
 [ 7 ,  11 ] . Both treatments with full opioid agonists (e. g., metha-
done) and partial agonist/antagonist (buprenorphine) have been 
found to be eff ective in reducing substance use and improving 
somatic, psychiatric as well as social functioning  [ 2 ,  12 – 14 ] . 
However the increasing level of diversion  [ 8 ,  15 ,  16 ] and the risk 
of fatal outcomes in opioid maintenance treatment have raised 
concerns about safety issues in the treatment of opioid depend-
ence.
 The combination of the partial mu-agonist/kappa-antagonist 
buprenorphine with the full mu-antagonist naloxone in a ratio 
of 4:1 was developed to improve treatment outcomes and to 
reduce the risk of diversion  [ 17 ,  18 ] . When the combination is 
administered sublingually as prescribed, naloxone is inactive 
because of its low sublingual bioavailability  [ 19 ] and only the 
eff ects of buprenorphine are experienced  [ 16 ,  20 ] blocking most 
of the mu-receptors  [ 12 ] . But when the medication is adminis-
tered parenterally (intravenous or nasal) the eff ects of naloxone 
are experienced for the fi rst 15–90 min  [ 21 ] . Both buprenor-
phine and naloxone have a very high bioavailability but naloxone 
binds more rapidly to the opioid mu-receptors than buprenor-
phine causing precipitated withdrawal if the user has full ago-
nists in the body  [ 16 ,  18 ] . Thus the combination of buprenorphine 
with naloxone is expected to reduce the risk of intravenous or 
nasal misuse  [ 19 ] . The combination minimizes the risk of opioid 
overdose and diversion by making it unattractive for selling 
 [ 17 ,  21 ] because of the unpleasant experience directly after 
parenteral abuse  [ 18 ,  21 ] . In addition the potential pleasurable 
eff ects of buprenorphine are diminished due to the smaller and 
delayed agonist eff ects after the subsiding antagonistic eff ect of 
naloxone  [ 21 ] .
 While a number of randomized clinical trials  [ 2 ,  12 ,  17 ,  22 ] dem-
onstrated the overall effi  cacy of buprenorphine-naloxone in the 
treatment of opioid dependence, to date no non-interventional 
observational studies on the eff ectiveness and safety of the novel 
buprenorphine-naloxone combination refl ecting “real world” 
conditions with a profound and comprehensive assessment both 
for physicians and patients have been published. Such studies 
are essential to verify clinical trial results and to receive reliable 
safety data from routine care treatment. The study was designed 
to collect comprehensive safety and eff ectiveness data on a large 
patient sample in offi  ce-based routine opioid drug dependence 
treatment with buprenorphine-naloxone over a 12-month 
period (2008–2010).
 Methods
 ▼
 Study goals
 The primary objectives of the non-interventional study was to 
describe the retention rate of patients pre-treated with 
buprenorphine, methadone, levo-methadone or another main-
tenance drug after 12 months of treatment with buprenorphine-
naloxone under real-life conditions and to collect comprehensive 
safety data during switch to and treatment with buprenorphine-
naloxone.
 The secondary objectives were to describe the switch to the new 
medication in terms of dosing, mode of prescription and subjec-
tive eff ects. Data on eff ectiveness, acceptance and tolerance of 
opioid dependence treatment with buprenorphine-naloxone 
should be examined regarding met and unmet needs.
 Study design
 The study was a nationwide, prospective 12-month observa-
tional, non-interventional, post-authorization safety study 
(PASS) with patients currently in drug dependence treatment 
with another medication such as d/l-methadone, levo-metha-
done or buprenorphine for whom a switch to buprenorphine-
naloxone was indicated and planned (  ●  ▶   Fig. 1 ). A comprehensive 
paper-based clinical research form was used for data capture. 
The study was part of the Risk Management Plan (RMP) for the 
newly marketed product buprenorphine-naloxone (Suboxone ® ) 
and therefore a requirement of the European Medicine Agency 
(EMA). The study is registered with the National Institute of 
Health (NIH) at ClinicalTrials.gov (NCT00723749).
 Study population
 From N = 69 physicians working in addiction medicine and quali-
fi ed pursuant to German Controlled Substances Regulation 
(Betäubungsmittelverordnung, BtMVV) § 5 (2) (1) (6) and with 
authorization granted by the Association of Statutory Health 
Insurance Physicians (Kassenärztliche Vereinigung, KV) N = 384 
opioid-dependent patients were enrolled (total population). All 
patients over 15 years of age who had consented to opioid drug 
dependence treatment within the scope of medical, social and 
psychotherapeutic measures, for whom the switch to buprenor-
phine-naloxone was indicated and planned and who had signed 
the informed consent form could be included. The participating 
physicians were not subject to directives in terms of the use of 
buprenorphine-naloxone and prescribed the medication in the 
form of a conventional, commercially available product. Thera-
peutic indications and contraindications for opioid dependence 
treatment according to the Summary of Product Characteriza-
tion (SmPC) for buprenorphine-naloxone and national treat-
Recruitment of sites (N=69/70)
Jan–Dec 2008
Recruitment of patients (N=384/300)
Mar 2008–Dec 2009
Physician’s
Questionnaire
Patient’s
Questionnaire
Urine Drug
screening
Final Report
(n=337 eligible datasets)
Jul 2011
(End of study Aug 2011)
Laboratory
Documentation
Observational period:
12 Months with 12 Visits
Mar 2008–Dec 2010
Site Evaluation Questionnaire
 Fig. 1  Design of the non-interventional study with buprenorphine-
naloxone. 
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ment guidelines had to be observed when selecting patients for 
participation in the non-interventional study.
 Of this total population n = 47 datasets were excluded from the 
fi nal analysis. Reasons were treatment not started (only baseline 
documentation available, n = 18), missing fi nal documentation 
(month 12 or drop-out, n = 21) and incomplete documentation 
(no documentation of induction phase and follow-up documen-
tation, n = 8).
 The fi nal analysis population of n = 337 eligible datasets contains 
all patients with written informed consent, as approved by the 
ethics committee of the Ludwig-Maximilian University in 
Munich, as well as complete study documentation for at least 
baseline (day 0), start of treatment with buprenorphine-
naloxone (day 1) and the fi nal documentation either as end-of-
observation (month 12) or drop-out documentation. For n = 3 
patients day 1 documentation was missing and documentation 
of day 2 of treatment with buprenorphine-naloxone was used 
instead.
 Assessments
 Physicians questionnaire (third-party assessment)
 The treating physicians informed eligible patients about the pur-
pose of the study, the data collection procedure and the data 
privacy protection. Only after agreeing to all aspects and signing 
the informed consent form the baseline assessment, which was 
conducted before switching the patient to buprenorphine-
naloxone, could be commenced.
 The physician’s questionnaire for evaluation of the patients was 
a paper-based assessment tool specially developed for the non-
interventional study with 45 pages including 12 sections with 
several standardized instruments to document the following 
patient parameters: socio-demographics, substance use history, 
treatment history, co-morbidities, co-medication, concomitant 
drug use, urine drug screening, main reason for switch to 
buprenorphine-naloxone, treatment with buprenorphine-
naloxone, premature discontinuation before end of observation, 
eff ectiveness measures with modifi ed Clinical Global Impres-
sion (mCGI), Objective Opiate Withdrawal Scale (OOWS), and 
safety. It was the physician’s decision which treatment data 
were transferred from the patient’s medical chart to the ques-
tionnaire.
 The CGI  [ 23 ] is a standard measure for global assessments of ill-
ness consisting of 3 diff erent global measures. In the study a 
modifi cation of the Clinical Global Impression Severity scale 
(CGI-S) and a modifi cation of the Clinical Global Impression 
Improvement scale (CGI-I) was used. The OOWS  [ 24 ] is a stand-
ardized scale for measuring the physically observable signs of 
opiate withdrawal for rating by the physician.
 All adverse events (non-serious and serious including adverse 
drug reactions and pregnancies) were listed as they were spon-
taneously reported and documented at each visit by the treating 
physician.
 Patients questionnaires (self assessment)
 During the 12-month observational period all patients were 
asked to complete 4 standardized questionnaires in accordance 
with the schedule of observation points (  ●  ▶   Fig. 2 ): 1) Short Form 
36 – Health Survey (SF-36)  [ 25 ] , a 36-item self-assessment ques-
tionnaire to survey the current health status with 2 modifi ed 
indication specifi c questions in reference to drug dependence; 
2) Subjective Opiate Withdrawal Scale (SOWS)  [ 24 ] , the subjec-
tive counterpart of the OOWS is a standardized scale for measur-
ing the intensity of symptoms of opiate withdrawal from the 
perspective of the patient; 3) revised psychiatric Symptom 
Check-List (SCL-90R)  [ 26 ,  27 ] , a standardized self-assessment 
tool to measure subjective impairment due to somatic and psy-
chiatric symptoms; 4) visual analogue scale for craving (VAS 
Craving), an instrument specially invented for the non-interven-
tional study by the fi rst author containing twelve 100-mm visual 
analogue scales for the substances alcohol, cannabis, ampheta-
mines, hallucinogens, cocaine, barbiturates, benzodiazepines, 
opiates, d/l-methadone/levo-methadone, buprenorphine, 
codeine/DHC and other. Patients were asked to visualize their 
current craving for each of the listed substances.
 Assessment schedule
 To ensure eligible and valid data collection for comprehensive 
evaluation of induction and course of drug dependence treat-
ment with buprenorphine-naloxone compared to baseline data 
before switch to the new medication, physician’s and patient’s 
questionnaires were scheduled for specifi c time points of obser-
vation (  ●  ▶   Fig. 2 ).
 Statistics and analysis
 Except for socio-demographics, retention rate, regular end of 
treatment and safety all comparisons were made between base-
line (day 0) and fi nal assessment as regular end of observation 
(month 12) or premature discontinuation documentation (drop-
Method
Points of
observation
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 Visit 10 Visit 11 Visit 12
Day 0
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
XX
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Day 1 Day 2 Day 3 Day 5 Day 7 Week 2 Week 4 Week 8 Week 12 Month 6 Month 12 or
Drop out documentation
Patients informed consent (IC)
Socio-demographics
Addiction/medical history
Drug, alcohol, tobacco use
Vital parameters
Physical examination
Co-morbidities
Co-medications
Urine drug screening
Laboratory screening
SF-36 Health Survey
OOWS/SOWS
VAS Craving
SCL-90R
CGI/CGI-I
AE/SAE
Course of therapy
Reason for drop out
Dosing, mode of allocation, cost unit
 Fig. 2  Flow chart parameters, methods and time 
points of observation. 
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out) for the total sample as well as for the analysis groups. Anal-
yses concerning treatment with buprenorphine-naloxone used 
day 1/start of treatment as baseline measures.
 Single and multinomial logistic regression and chi-square tests 
were used for descriptive correlations between the defi ned anal-
ysis groups, start and end of observation. For numerical param-
eters, sample statistics, mean and standard deviation, minimum 
and maximum were calculated. For categorical data, absolute 
and relative frequencies were calculated. Data generated repeat-
edly in the course of time were evaluated per observation point. 
The diff erences between baseline and fi nal assessment are shown 
for specifi c numerical data as absolute and relative diff erence.
 Retention rates were estimated using Kaplan-Meier method and 
are presented as survival curves and 12-month survival esti-
mates.
 The options “not tested” and “no test” were set to missing values. 
For the option “no change” the status from the previous visit was 
carried forward.
 Statistical signifi cance was defi ned as p-values < 0.05. Statistical 
analysis was done with STATA/SE 9  [ 28 ] .
 Measures and specifi cations
 Retention rate:  percentage of patients still in drug depend-
ence treatment with buprenorphine-naloxone at the end of the 
observation period or who completed treatment after achieving 
a successful therapeutic outcome (regular end of treatment/
abstinence).
 Safety:  percentage of all documented non-serious and serious 
adverse events including adverse drug reactions, which were 
coded using MedDRA version 11.1  [ 29 ] .
 Eff ectiveness:  improvement of scores from the standardized 
instruments mCGI for general health, SCL-90R for mental health, 
OOWS and SOWS for withdrawal; regular end of treatment 
(patient abstinent) documented by the treating physician in the 
fi nal assessment as premature discontinuation documentation 
was defi ned as positive treatment outcome and patients were 
counted as completers.
 Quality of life (QoL):  improvement of scores from the stand-
ardized instrument SF-36 comparing baseline with the fi nal 
assessment.
 Acceptance and tolerance:  reduction of concomitant drug use 
measured by urine drug screening, craving for illicit substances 
measured by the standardized instrument VAS craving and 
number of fresh needle marks.
 Analysis groups (post-hoc generation)
 Completers:  patients still in drug dependence treatment with 
buprenorphine-naloxone at the end of observation (month 12) 
including patients with dropout reason regular end of treatment 
(patient abstinent from all illegal drugs including opiate-substi-
tution).
 Non-completers:  patients with documented premature dis-
continuation of treatment with buprenorphine-naloxone for any 
reason other than regular end of treatment (patient abstinent).
 Pre-treated:  patients with documented current maintenance 
pharmacotherapy at baseline.
 Untreated:  patients without any documented previous main-
tenance pharmacotherapy at baseline [patients with no current 
maintenance treatment at study entry, but with a history of pre-
vious substitution treatment(s) are excluded from analysis 
between pre-treated and untreated patients].
 Buprenorphine:  patients in treatment with the mono com-
pound buprenorphine at baseline.
 (Levo-)methadone:  patients in treatment with d/l-methadone 
or levo-methadone at baseline.
 The term  analysis groups refers to the above defi ned groups of 
completer/non-completer, pre-treated/untreated and buprenor-
phine/(levo-)methadone.
 Results
 ▼
 Data from N = 337 eligible patients was examined.
 Patient population
 Socio-demographics
  ●  ▶   Table 1 summarizes patient characteristics at baseline for the 
total sample and all analysis groups. Most of the patients were 
male and in their mid-thirties, ranging from 18–62 years, and 
German nationality. Completers were older, married or living 
with a partner, working in a full-time job and living in their own 
fl at. Higher rates of the more unfavourable characteristics such 
as unemployment, being divorced or single and being homeless 
are found in the group of non-completers.
 Addiction history
 As shown in   ●  ▶   Table 1 N = 244 patients were in maintenance 
treatment with buprenorphine (66.4 %), d/l-methadone (20.9 %), 
levo-methadone (9.8 %) or another maintenance drug (2.9 %) at 
baseline. For n = 49 patients the treatment with buprenorphine-
naloxone was their fi rst opioid drug dependence treatment and 
n = 44 patients were previously but not at baseline in mainte-
nance treatment. Most of the participating patients had a long 
opioid addiction history from almost 14 years on average, rang-
ing from 4 months to 50 years. Patients switched from the 
mono-compound buprenorphine and pre-treated patients had a 
signifi cantly longer drug addiction history [patients with no 
current maintenance treatment at study entry, but with a his-
tory of previous substitution treatment(s) are excluded from 
analysis between pre-treated and untreated patients].
 Almost all patients used opioids in their life (94.6 %) with no dif-
ference within the analysis groups. Non-completers revealed 
signifi cantly higher rates in the use of benzodiazepines (72.7 % 
vs. 56.5 % completer, p = 0.003), cocaine (85.5 % vs. 64.9 %, 
p ≤ 0.001), amphetamines (67.2 % vs. 36.8 %, p ≤ 0.001), hallucino-
gens (42.5 % vs. 25.8 %, p = 0.002), codeine (36.1 % vs. 18.8 %, 
p = 0.001), barbiturates (29.0 % vs. 11.2 %, p ≤ 0.001). Pre-treated 
patients revealed signifi cantly higher rates in the use of cocaine 
(75.4 % vs. 59.6 % untreated, p = 0.039), benzodiazepines (64.2 % 
vs. 47.9 %, p = 0.035) and codeine (27.4 % vs. 10.9 %, p = 0.018). Sig-
nifi cantly higher rates of life-time cannabis use were found in 
the group of patients switched from buprenorphine [91.9 % vs. 
79.7 % (levo-)methadone, p = 0.008].
Th
is
 d
oc
um
en
t w
as
 d
ow
nl
oa
de
d 
fo
r p
er
so
na
l u
se
 o
nl
y.
 U
na
ut
ho
riz
ed
 d
is
tri
bu
tio
n 
is
 s
tri
ct
ly
 p
ro
hi
bi
te
d.
98 Original Paper
 Apelt SM et al. Safety, Eff ectiveness and Tolerance … Pharmacopsychiatry 2013; 46: 94–107 
  Ta
bl
e 
1   
 Pa
tie
nt
’s
 c
ha
ra
ct
er
is
tic
s 
at
 b
as
el
in
e.
 
  
  To
ta
l S
am
pl
e  
  Co
m
pl
et
er
s  
  N
on
-C
om
pl
et
er
s  
  p  
  Pr
e-
Tr
ea
te
d  
  U
n-
Tr
ea
te
d  
  p  
  Bu
pr
en
or
ph
in
e  
  (L
ev
o-
) M
et
ha
do
ne
  
  
  
  33
7*
  
  19
5  
  14
2  
  24
4  
  49
  
  16
2  
  75
  
  p  
  Ag
e 
in
 y
ea
rs
 [m
ea
n 
(S
D
)]
 N
 =
 3
36
  
  35
.1
 (8
.8
)  
  36
 (9
.0
)  
  33
.9
 (8
.4
)  
   0.
02
9 
  
  35
.7
 (8
.8
)  
  32
.6
 (8
.6
)  
   0.
02
5 
  
  36
.8
 (8
.8
)  
  33
.5
 (7
.8
)  
   0.
00
6 
  
  M
al
e 
[n
 ( 
%
)]
 N
 =
 3
37
  
  25
8 
(7
6.
6)
  
  15
4 
(7
9.
0)
  
  10
4 
(7
3.
2)
  
  0.
22
0  
  19
2 
(7
8.
7)
  
  36
 (7
3.
5)
  
  0.
42
2  
  11
9 
(7
3.
5)
  
  66
 (8
8.
0)
  
   0.
01
2 
  
  G
er
m
an
 n
at
io
na
lit
y 
[n
 ( 
%
)]
 N
 =
 3
36
  
  28
1 
(8
3.
6)
  
  16
2 
(8
3.
1)
  
  11
9 
(8
4.
4)
  
  0.
74
7  
  19
6 
(8
0.
3)
  
  43
 (8
7.
8)
  
  0.
22
1  
  13
4 
(8
2.
7)
  
  56
 (7
4.
7)
  
  0.
14
8  
  BM
I [
m
ea
n 
(S
D
)]
 N
 =
 3
32
  
  23
.8
 (3
.9
)  
  24
 (3
.9
)  
  23
.5
 (3
.9
)  
  0.
21
4  
  23
.9
 (3
.9
)  
  23
.2
 (3
.9
)  
  0.
22
6  
  23
.9
 (4
.1
)  
  24
 (3
.5
)  
  0.
91
1  
  M
ar
ita
l s
ta
tu
s 
[n
 ( 
%
)]
 N
 =
 3
34
  
  
  
  
  
  
  
  
  
  
  
  – 
Si
ng
le
  
  20
1 
(6
0.
2)
  
  10
8 
(5
6.
3)
  
  93
 (6
5.
5)
  
  0.
08
8  
  14
5 
(6
0.
2)
  
  29
 (5
9.
2)
  
  0.
89
8  
  91
 (5
7.
2)
  
  47
 (6
2.
7)
  
  0.
43
0  
  – 
M
ar
rie
d/
liv
in
g 
to
ge
th
er
  
  10
2 
(3
0.
6)
  
  69
 (3
5.
9)
  
  33
 (2
3.
2)
  
   0.
01
3 
  
  73
 (3
0.
3)
  
  16
 (3
2.
7)
  
  0.
74
4  
  49
 (3
0.
8)
  
  24
 (3
2.
0)
  
  0.
85
5  
  – 
D
iv
or
ce
d  
  30
 (9
.0
)  
  14
 (7
.3
)  
  16
 (1
1.
3)
  
  0.
20
9  
  23
 (9
.5
)  
  4 
(8
.2
)  
  0.
76
2  
  19
 (1
1.
9)
  
  4 
(5
.3
)  
  0.
11
3  
  Ch
ild
re
n 
[n
 ( 
%
)]
 N
 =
 3
31
  
  12
0 
(3
6.
3)
  
  70
 (3
7.
0)
  
  50
 (3
5.
2)
  
  0.
73
2  
  90
 (3
7.
8)
  
  13
 (2
6.
5)
  
  0.
13
4  
  68
 (4
2.
5)
  
  22
 (3
1.
0)
  
  0.
09
8  
  O
cc
up
at
io
n 
[n
 ( 
%
)]
 N
 =
 3
37
  
  
  
  
  
  
  
  
  
  
  
  – 
Fu
ll-
tim
e 
jo
b  
  77
 (2
2.
8)
  
  51
 (2
6.
1)
  
  26
 (1
8.
3)
  
  0.
09
0  
  60
 (2
4.
6)
  
  8 
(1
6.
3)
  
  0.
21
1  
  49
 (3
0.
3)
  
  11
 (1
4.
7)
  
   0.
01
0 
  
  – 
Pa
rt
-t
im
e 
jo
b  
  48
 (1
4.
2)
  
  24
 (1
2.
3)
  
  24
 (1
6.
9)
  
  0.
23
3  
  40
 (1
6.
4)
  
  3 
(6
.1
)  
  0.
06
4  
  28
 (1
7.
3)
  
  11
 (1
4.
7)
  
  0.
61
3  
  – 
U
ne
m
pl
oy
ed
  
  17
9 
(5
3.
1)
  
  10
0 
(5
1.
3)
  
  79
 (5
5.
6)
  
  0.
42
9  
  12
2 
(5
0.
0)
  
  29
 (5
9.
2)
  
  0.
24
0  
  69
 (4
2.
6)
  
  48
 (6
4.
0)
  
   0.
00
2 
  
  Re
si
de
nt
ia
l s
ta
tu
s 
[n
 ( 
%
)]
 N
 =
 3
37
  
  
  
  
  
  
  
  
  
  
  
  – 
O
w
n 
fl a
t  
  24
6 
(7
3.
0)
  
  15
0 
(7
6.
9)
  
  96
 (6
7.
6)
  
  0.
05
7  
  18
5 
(7
5.
8)
  
  32
 (6
5.
3)
  
  0.
12
5  
  13
7 
(8
4.
6)
  
  45
 (6
0.
0)
  
    <
 0
.0
01
   
  – 
W
ith
 fa
m
ily
/f
rie
nd
s  
  63
 (1
8.
7)
  
  35
 (1
7.
9)
  
  28
 (1
9.
7)
  
  0.
68
1  
  42
 (1
7.
2)
  
  14
 (2
8.
6)
  
  0.
06
5  
  15
 (9
.3
)  
  23
 (3
0.
7)
  
    < 
0.
00
1 
  
  – 
H
om
el
es
s  
  5 
(1
.5
)  
  0 
(0
.0
)  
  5 
(3
.5
)  
   0.
00
8 
  
  3 
(1
.2
)  
  1 
(2
.0
)  
  0.
65
5  
  1 
(0
.6
)  
  2 
(2
.7
)  
  0.
18
9  
  Ye
ar
s 
of
 d
ep
en
de
nc
e 
[m
ea
n 
(S
D
)]
 N
 =
 3
11
  
  13
.8
 (8
.7
)  
  14
.6
 (8
.5
)  
  12
.8
 (8
.8
)  
  0.
07
7  
  14
.9
 (8
.9
)  
  8.
5 
(6
.4
)  
    <
 0
.0
01
   
  15
.9
 (9
.3
)  
  12
.7
 (6
.8
)  
   0.
00
9 
  
  In
 m
ai
nt
en
an
ce
 tr
ea
tm
en
t w
ith
 [n
 ( 
%
)]
 N
 =
 2
44
  
  
  
  
  
  
  
  
  
  
  
  – 
Bu
pr
en
or
ph
in
e  
  16
2 
(6
6.
4)
  
  93
 (6
6.
4)
  
  69
 (6
6.
4)
  
  0.
98
9  
  16
2 
(6
6.
4)
  
  0 
(0
.0
)  
  
  16
2 
(1
00
.0
)  
  0 
(0
.0
)  
  
  – 
D
/l 
m
et
ha
do
ne
  
  51
 (2
0.
9)
  
  29
 (2
0.
7)
  
  22
 (2
1.
2)
  
  0.
93
3  
  51
 (2
0.
9)
  
  0 
(0
.0
)  
  
  0 
(0
.0
)  
  51
 (6
8.
0)
  
  
  – 
Le
vo
-m
et
ha
do
ne
  
  24
 (9
.8
)  
  18
 (1
2.
9)
  
  6 
(5
.8
)  
  0.
06
6  
  24
 (9
.8
)  
  0 
(0
.0
)  
  
  0 
(0
.0
)  
  24
 (3
2.
0)
  
  
  W
ith
ou
t p
rio
r m
ai
nt
en
an
ce
 tr
ea
tm
en
t [
n 
( %
)]
 N
 =
 3
37
  
  49
 (1
4.
5)
  
  29
 (1
4.
9)
  
  20
 (1
4.
1)
  
  0.
95
8  
  0 
(0
.0
)  
  49
 (1
00
.0
)  
  
  0 
(0
.0
)  
  0 
(0
.0
)  
  
   ≥
 1
 p
rio
r d
et
ox
ifi 
ca
tio
n 
at
te
m
pt
 [n
 ( 
%
)]
 N
 =
 2
54
  
  20
9 
(8
2.
3)
  
  11
9 
(7
9.
9)
  
  90
 (8
5.
7)
  
  0.
22
9  
  15
8 
(8
4.
5)
  
  15
 (5
5.
6)
  
    <
 0
.0
01
   
  10
5 
(8
3.
3)
  
  48
 (8
7.
3)
  
  0.
50
0  
   ≥
 1
 p
rio
r w
ith
dr
aw
al
 a
tt
em
pt
 [n
 ( 
%
)]
 N
 =
 2
29
  
  14
2 
(6
2.
0)
  
  83
 (6
0.
6)
  
  59
 (6
4.
1)
  
  0.
58
8  
  10
8 
(6
5.
1)
  
  8 
(3
0.
8)
  
   0.
00
1 
  
  72
 (6
5.
5)
  
  34
 (6
5.
4)
  
  0.
99
3  
   ≥
 1
 p
rio
r s
el
f d
et
ox
ifi 
ca
tio
n 
at
te
m
pt
 [n
 ( 
%
)]
 N
 =
 1
97
  
  15
1 
(7
6.
7)
  
  85
 (7
7.
3)
  
  66
 (7
5.
9)
  
  0.
81
6  
  10
5 
(7
5.
5)
  
  17
 (6
5.
4)
  
  0.
27
9  
  63
 (7
0.
0)
  
  38
 (8
6.
4)
  
   0.
03
9 
  
  H
ep
at
iti
s 
C 
in
fe
ct
io
n 
[n
 ( 
%
)]
 N
 =
 3
35
  
  12
1 
(3
6.
1)
  
  62
 (3
1.
8)
  
  59
 (4
2.
1)
  
   0.
00
9 
  
  96
 (4
3.
2)
  
  9 
(2
7.
3)
  
  0.
08
2  
  63
 (4
3.
2)
  
  30
 (4
3.
5)
  
  0.
96
4  
  H
IV
 in
fe
ct
io
n 
[n
 ( 
%
)]
 N
 =
 2
72
  
  4 
(1
.2
)  
  2 
(1
.0
)  
  2 
(1
.4
)  
  0.
63
7  
  4 
(1
.9
)  
  0 
(0
.0
)  
  0.
45
4  
  3 
(2
.2
)  
  0 
(0
.0
)  
  0.
22
8  
  Ps
yc
hi
at
ric
 c
om
or
bi
di
ty
 [n
 ( 
%
)]
 N
 =
 3
37
  
  19
3 
(5
7.
3)
  
  10
6 
(5
4.
4)
  
  87
 (6
1.
3)
  
  0.
19
5  
  14
4 
(5
9.
0)
  
  27
 (5
5.
1)
  
  0.
61
2  
  93
 (5
7.
4)
  
  47
 (6
2.
7)
  
  0.
44
4  
  N
um
be
r o
f p
sy
ch
ia
tr
ic
 c
om
or
bi
di
tie
s 
[m
ea
n 
(S
D
)]
  
  2 
(1
.5
)  
  1.
9 
(1
.6
)  
  2.
1 
(1
.5
)  
  0.
53
8  
  2.
1 
(1
.6
)  
  1.
4 
(0
.7
)  
   0.
02
7 
  
  1.
8 
(1
.4
)  
  2.
7 
(1
.9
)  
   0.
00
5 
  
 * 
El
ig
ib
le
 d
at
as
et
s
Pe
rc
en
ta
ge
s 
re
fe
r t
o 
no
n-
m
iss
in
g 
to
ta
l a
nd
 v
ar
y 
w
ith
in
 a
na
ly
si
s 
gr
ou
ps
 
Th
is
 d
oc
um
en
t w
as
 d
ow
nl
oa
de
d 
fo
r p
er
so
na
l u
se
 o
nl
y.
 U
na
ut
ho
riz
ed
 d
is
tri
bu
tio
n 
is
 s
tri
ct
ly
 p
ro
hi
bi
te
d.
99Original Paper
 Apelt SM et al. Safety, Eff ectiveness and Tolerance … Pharmacopsychiatry 2013; 46: 94–107 
 The average daily dosage for pre-treated d/l-methadone patients 
was 41.8 ± 37.2 mg (2–160 mg), levo-methadone patients 
26.5 ± 17.1 mg (4–60 mg) and buprenorphine patients 7.7 ± 4.3 mg 
(1–24 mg) at baseline.
 Retention rate and drop-out
 Retention rate
 Of the total eligible patients n = 181 were still in treatment at the 
end of observation after 12 months of treatment with buprenor-
phine-naloxone and n = 14 patients terminated their treatment 
during the observation period because they were rated as absti-
nent by their treating physician. The 12-month retention rate, 
analyzed with Kaplan-Meier estimator, was 57.1 % for the total 
analysis population (  ●  ▶   Fig. 3 ). There were no diff erences 
between pre-treated and untreated patients (  ●  ▶   Fig. 3 ). A slightly 
higher retention rate was found in (levo-)methadone patients 
(  ●  ▶   Fig. 4 ).
 Reasons for dropout
 N = 142 patient terminated treatment before end of observation. 
The most frequently documented reasons for drop out were “lost 
to follow up” (16.7 %), “concomitant drug use/relapse” (12.2 %), 
“side eff ects” (12.2 %) and “non-compliance/disciplinary reasons” 
(10.9 %). Signifi cantly more untreated patients (16.7 % vs. 4.6 % pre-
treated, p = 0.033) were rated as abstinent by the treating physician.
 No deaths occurred during the entire observational period. Only 
n = 1 hospitalization and n = 3 pregnancies led to premature ter-
mination of treatment with buprenorphine-naloxone.
 Safety
 Safety reporting for non-interventional studies is done accord-
ing to regulations for routine care practice in Germany. The 
research forms of this study contained special sheets for docu-
mentation of all adverse events and the physician’s folder pro-
vided reporting forms for serious adverse events but it was the 
physician’s decision if an incident during the observation period 
required documentation and reporting, respectively. Therefore 
only non-serious and serious adverse events documented and 
reported by the treating physician could be included in the anal-
ysis. In this paper the adverse events reported were evaluated 
for the analysis population only.
 Serious adverse events (SAE)
 For n = 4 (1.2 %) of the patients from the analysis population 
(N = 337) there were n = 4 serious adverse events reported during 
the complete observational period including 30 days post-study 
time. The events, listed as system organ class and the term 
reported by the treating physician (in brackets) were n = 1 psy-
chiatric disorder (hospitalization because of suspected adjust-
ment disorder), n = 1 social circumstances (concomitant drug 
use), n = 1 surgical and medical procedure (stay in hospital) and 
n = 1 nervous system disorder (epilepsy). One event was reported 
with certain correlation to the study drug (concomitant drug 
use), one with likely correlation (hospitalization because of sus-
pected adjustment disorder), one with unlikely correlation (epi-
lepsy) and one with unknown relation to the study drug (stay in 
hospital).
12-Month Retention Rate
of pre-treated (N=244) and untreated (N=49) patients
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 Fig. 3  12-month retention of the total analysis 
population (N = 337), pre-treated (n = 244) and 
untreated (n = 49) patients. 
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 Fig. 4  12-month retention of buprenorphine 
(n = 162) and (levo-)methadone (n = 75) patients. 
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 No diff erences within the analysis groups were found in refer-
ence to the occurrence of SAEs. No deaths were reported during 
the study.
 Non-serious adverse events (NSAE)
 For n = 59 (17.5 %) patients n = 141 non-serious adverse events 
were reported. NSAEs with a threshold of over 5.0 % were psychi-
atric disorders (17.7 %), social circumstances (15.6 %, most of 
them concomitant drug use/non-compliance), gastrointestinal 
disorders (12.8 %), infections and infestations (12.8 %), nervous 
system disorders (9.9 %) and musculoskeletal and connective tis-
sue disorders (9.2 %). 5 of the NSAEs were reported as certainly 
correlated to the study drug, n = 27 likely related, n = 32 possibly 
related, n = 67 unlikely related and n = 10 were reported as 
unknown concerning relation to the study drug. Signifi cantly 
more non-completers (23.2 % vs. 13.3 % completers, p = 0.018) 
and pre-treated patients (20.5 % vs. 8.2 % untreated, p = 0.042) 
were reported with non-serious adverse events. No diff erence 
was found between buprenorphine and (levo-) methadone 
patients concerning number of NSAEs.
 Treatment with buprenorphine-naloxone
 Reason for switch to buprenorphine-naloxone
 The main reasons for switching to buprenorphine-naloxone 
were long-term maintenance treatment with or without absti-
nence as fi nal goal (28.8 %), prior maintenance treatment not 
successful (21.4 %), planned detoxifi cation treatment (17.8 %) 
and prevention of buprenorphine misuse (17.5 %). For 11.9 % the 
physicians reported “patient’s wish for take home” as reason for 
the switch to buprenorphine-naloxone.
 Dosing of buprenorphine-naloxone
 The mean induction dose of buprenorphine-naloxone was 
9.2 ± 5.1 mg per day with a maximum of 32.0 mg. This dose 
slightly increased to 9.6 mg on day 2 and 3 of the treatment with 
buprenorphine-naloxone and decreased continuously in the 
course of treatment to 7.7 mg per day. Non-completers received 
generally higher doses, but those non-completers who were still 
in treatment at month 6 (n = 37) received virtually the same dose 
as completers (  ●  ▶   Fig. 5 ). Patients switched from d/l-methadone or 
levo-methadone received higher doses of buprenorphine-naloxone 
than patients switched from the mono-compound buprenorphine 
(  ●  ▶   Fig. 6 ). Doses of previous buprenorphine patients did not 
change during the course of treatment with buprenorphine-
naloxone. Interestingly pre-treated and untreated patients’ dose of 
buprenorphine-naloxone did not  diff er (  ●  ▶   Fig. 7 ).
 Patients rated as abstinent during the observation period (n = 14) 
were not included in the analyses shown above. Their mean 
induction dose of buprenorphine-naloxone was 8.5 ± 6.3 mg 
which decreased rapidly to 7.0 ± 4.7 mg at day 7, 4.6 ± 2.6 mg at 
week 4 and 2.0 ± 1.6 mg at their fi nal assessment.
 Mode of prescription
 At the induction day most of the patients (87.1 %) received 
buprenorphine-naloxone on a daily basis at the practice of the 
treating physician and 8.4 % as take-home prescription. All of the 
take-home prescriptions were documented for pre-treated 
patients and signifi cantly more for buprenorphine patients (14.4 % 
vs. 5.3 % (levo-)methadone, p = 0.043). Take-home prescription 
increased during treatment with buprenorphine-naloxone and 
was documented for 25.1 % of the patients at the fi nal assessment. 
Signifi cantly more completers (30.1 % vs. 18.3 % non-completers, 
p = 0.014) received take-home at the time of their fi nal assess-
ment.
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 Quality of life
 SF-36
 As shown in   ●  ▶   Table 2 the scores of the standardized patient 
questionnaire SF-36 were relatively low at baseline but increased 
during treatment with buprenorphine-naloxone signifi cantly 
for all scales. There was no diff erence between completers and 
non-completers at baseline except for pain. At the fi nal assess-
ment completers had signifi cantly higher scores in all scales and 
non-completers revealed no substantial improvement from 
baseline to fi nal assessment.
 Pre-treated patients had higher scores at baseline but at the fi nal 
assessment untreated patients achieved higher scores in all 
scales of the SF-36 and signifi cantly for the scales emotional 
well-being and drug dependence compared to pre-treated 
patients.
 At baseline buprenorphine patients achieved signifi cantly higher 
rates compared to (levo-)methadone patients but no diff erence 
was found at the fi nal assessment. While (levo-)methadone 
patients improved signifi cantly in all scales, buprenorphine 
patients showed only for pain, social functioning, emotional role 
functioning and drug dependence signifi cant improvement from 
baseline to fi nal assessment.
 Eff ectiveness of the treatment with buprenorphine-
naloxone
 Mental health
 As shown in   ●  ▶   Table 3 the mean scores of the SCL-90-R at base-
line are higher in all scales for non-completers, untreated and 
(levo-)methadone patients. All patients achieved a signifi cant 
improvement of psychiatric distress at their fi nal assessment 
irrespective of analysis group.
 Modifi ed Clinical Global Impression – Severity scale 
(mCGI-S)
  ●  ▶   Fig. 8 shows the modifi ed CGI measuring the general health of 
the patient from the perspective of the physician. The categories 
were transformed to numeric scores (0 = very good to 
5 = extremely bad). There was no diff erence between completers 
and non-completers but untreated and (levo-) methadone 
patients received signifi cantly higher scores at baseline. Accord-
ing to the physicians the general health of all patients improved 
signifi cantly during treatment with buprenorphine-naloxone 
except for non-completers. Their general health slightly wors-
ened and the score was signifi cantly higher (p < 0.001) at the 
fi nal assessment compared to completers.
 Withdrawal
 SOWS:  The total score of the subjective opiate withdrawal 
scale at baseline was 17.2 ± 13.5 and decreased to 5.1 ± 8.4 at fi nal 
assessment. Non-completers achieved a signifi cantly higher 
score at baseline (19.0 ± 13.6 vs. 15.9 ± 13.4 completers, p = 0.043) 
and fi nal assessment (11.7 ± 11.7 vs. 3.9 ± 7.0, p < 0.001). Untreated 
patients (20.8 ± 14.7 vs. 14.9 ± 12.5 pre-treated, p = 0.005) and (levo-)
methadone patients (20.3 ± 13.2 vs. 11.8 ± 10.5 buprenorphine, 
p < 0.001) achieved a signifi cantly higher score at baseline but 
did not diff er from their comparison group at fi nal assessment. 
All groups, except non-completer, achieved a signifi cant reduc-
tion of subjective opiate withdrawal during the treatment with 
buprenorphine-naloxone.
 OOWS:  The total score of the objective opiate withdrawal scale 
reported by the treating physicians was 8.8 ± 8.1 at baseline and 
decreased signifi cantly to 2.2 ± 4.8 (p < 0.001). From the physi-
cian’s perspective there was no diff erence between completers 
and non-completers concerning opiate withdrawal at baseline, 
but at the fi nal assessment non-completers received a signifi -
cantly higher score (3.8 ± 6.2 vs. 1.1 ± 3.0 completers, p < 0.001). 
Untreated (12.7 ± 7.4 vs. 7.2 ± 7.6 pre-treated, p < 0.001) and (levo-) 
methadone (11.1 ± 7.7 vs. 4.9 ± 6.3 buprenorphine, p < 0.001) 
patients showed signifi cantly more withdrawal symptoms at 
baseline. At the end of the observation physicians saw no 
 diff erence between untreated and pre-treated patients, but in 
buprenorphine patients they identifi ed more objective 
 withdrawal symptoms [2.2 ± 4.4 vs. 1.1 ± 3.3 (levo-)methadone, 
p = 0.050].
 Regular end of treatment
 For n = 14 patients the premature discontinuation within the 
12-month observation period was the regular end of treatment 
with buprenorphine-naloxone because they were rated as absti-
nent by their treating physician (4.2 % of the total eligible patient 
population). Signifi cantly more patients without prior mainte-
nance treatment became abstinent (8.2 % vs. 2.1 % pre-treated, 
p = 0.002). No diff erence was found between patients with prior 
buprenorphine treatment and treatment with (levo-)metha-
done.
 Acceptance and tolerance
 Concomitant drug use
 According to the results of urine drug screenings (  ●  ▶   Table 4 ) 
approximately one-third of the patients had a current use of 
opioids and cannabis at baseline. Signifi cantly higher rates of 
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opioid use were found in non-completers and untreated patients. 
Signifi cantly more non-completers used cocaine and benzodi-
azepines, signifi cantly more untreated patients used benzodi-
azepines and amphetamines and signifi cantly more (levo-)
methadone patients used cannabis. During the treatment with 
buprenorphine-naloxone urine drug screenings revealed a sig-
nifi cant reduction of drug use for all illicit substances except 
barbiturates. Signifi cantly higher rates of opioid use, cocaine, 
benzodiazepines and amphetamines were found in non-compl-
eters compared to completers. Signifi cantly more (levo-)metha-
done patients were found to be active cannabis users at the fi nal 
assessment.
 Opiate craving (VAS)
 Patients reported the highest craving at baseline and the highest 
decrease of craving during treatment with buprenorphine-
naloxone for opiates (32.3 ± 33.2 vs. 7.2 ± 17.3, p < 0.001). Non-
completers (38.9 ± 35.4 vs. 27.6 ± 30.9 completers, p = 0.003) and 
untreated patients (46.4 ± 37.9 vs. 25.7 ± 29.7 pre-treated, 
p < 0.001) reported a signifi cantly higher total score at baseline, 
but only non-completers reported a relatively high craving score 
at the fi nal assessment (24.7 ± 32.5 vs. 4.2 ± 10.5 completers, 
p < 0.001). At the end of the observation untreated patients did 
not diff er from pre-treated patients concerning craving for opi-
ates. There was no diff erence found between buprenorphine and 
(levo-)methadone patients at baseline and fi nal assessment. 
Nevertheless the reduction of craving for opiates was signifi cant 
for all groups including non-completer.
 Fresh needle marks
 Physicians documented fresh needle marks for 13.5 % at base-
line, for slightly more non-completers (17.3 % vs. 10.8 % compl-
eters, p = 0.086) and signifi cantly more untreated patients (20.4 % 
vs. 9.5 % pre-treated, p = 0.029). Most of these patients had a pos-
itive urine drug screening for opioids (75.6 %).
 At the fi nal assessment physicians reported fresh needle marks 
for n = 10 patients, all of them were non-completers, n = 4 were 
pre-treated, n = 2 untreated and n = 4 were switched from 
buprenorphine. Most of these patients had positive drug screen-
ings for opioids (n = 7). Physicians reported no fresh needle 
marks for (levo-)methadone patients.
 Discussion
 ▼
 The results of this non-interventional study underline the over-
all eff ectiveness of opioid drug dependence treatment with the 
4:1 combination buprenorphine-naloxone. In line with fi ndings 
in a previous naturalistic study in routine care  [ 30 ] the 12-month 
retention rate of patients induced or switched to buprenor-
phine-naloxone was 55.7–62.0 % depending on previous mainte-
nance treatment. These rates are also in line with results on 
retention of patients receiving standard methadone treatment 
 [ 30 – 32 ] . No deaths occurred and the very low rate of adverse 
events emphasizes the high safety profi le of buprenorphine-
naloxone. Signifi cant improvements in almost all evaluated 
domains during the 12-month observation period, irrespective 
of study completion and previous maintenance treatment, ver-
ify the eff ectiveness of the medication found in previous clinical 
trials  [ 2 ,  12 ,  17 ,  19 ,  22 ] . As reported by Wittchen et al. 2008  [ 30 ] 
in their naturalistic study in 2 694 patients, the same proportion 
of patients (4.2 %) had achieved abstinence during the observa-
tional period. Since a certain period (e. g., 5 years) of abstinence 
is required to reduce the risk of future relapse  [ 3 ] we recom-
mend a follow-up study to verify the status of patients with 
documented regular end of treatment because of abstinence.
 Compared to international fi ndings on dosing of buprenorphine-
naloxone between 16–24 mg/day  [ 33 ] , patients observed in this 
non-interventional study received lower doses of 10 mg/day on 
average, which decreased to an average of 8 mg/day at the end of 
the 12-month observation, irrespective of study completion and 
previous maintenance treatment. Patients switched from d/l-
methadone or l-methadone received signifi cantly higher doses 
of 11 mg/day on average decreasing until end of study to slightly 
but non-signifi cantly higher doses of approximately 9 mg/day. 
Dosing is a critical aspect in the treatment and retention of 
 opioid dependent patients – it is important to alleviate the 
patient’s cravings and withdrawal symptoms. The data of this 
non-interventional study reveal a signifi cant relation between 
study completion status and withdrawal symptoms as well as 
opioid craving scores. Non-completers started with signifi cantly 
higher subjective opiate withdrawal symptoms and craving 
which was still signifi cantly higher at the time of their prema-
ture discontinuation of treatment with buprenorphine-
naloxone. According to the physicians there was no diff erence 
concerning objective opiate withdrawal symptoms between 
non-completers and completers at baseline, but at the fi nal 
Untreated
Pre-treated
Non-completer
Completer
Total
0
Scores: 0-very good, 1-rather good, 2-part/part,
3-rather bad, 4-very bad, 5-extremely bad
0.5
2.3 1.0
1.5
1.7
1.7
0.7
1.8 1.9
1.0
1.0
p<0.001
p<0.001
p<0.001
p<0.001
p=0.063
1 1.5 2
Baseline Final Assessment
CGI Scores
General health of the patients measured  by mCGI and transformed to
scores at baseline and final assessment
2.5 3.5 43
 Fig. 8  Modifi ed CGI score at baseline and fi nal 
assessment for all eligible patients (N = 337). 
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assessment they reported signifi cantly higher objective with-
drawal symptoms for non-completers. Completers achieved a 
signifi cant reduction of subjective opiate withdrawal during the 
treatment with buprenorphine-naloxone, however the reduc-
tion of craving for opiates was signifi cant for all groups including 
non-completers compared to baseline.
 Take-home prescription is an important factor for reintegration 
into social and occupational life, because it enables the patient 
to start or stay in employment due to more fl exibility in daily 
routine. 11.9 % of all eligible patients wanted to switch to 
buprenorphine-naloxone for take-home prescription. At start of 
treatment with buprenorphine-naloxone a minority of patients 
received take-home prescription (8.4 %) and all of these were 
pre-treated patients. At the end of the observation 25.1 % of all 
observed patients received take-home prescription. The deci-
sion for a take-home prescription is discretionary to the treating 
physician in compliance with §5 (8) BtMVV (Controlled Sub-
stances Prescription Regulation). The patient may receive a take-
home prescription for up to 7 consecutive days if the patient is in 
stable maintenance treatment, without relevant concomitant 
drug use and use of other substances that interact with the 
maintenance drug and therefore endanger his health  [ 34 ] .
 Psychiatric comorbidities are very common in this patient popu-
lation  [ 35 ] . At baseline the scores of the SCL-90-R were relatively 
low with higher rates in all scales for non-completers, untreated 
patients and (levo-)methadone patients. Apart from non-compl-
eters all eligible patients achieved a signifi cant reduction of 
 psychiatric distress at their fi nal assessment. However non-com-
pleters did reach lower scores (except for the scale interpersonal 
sensitivity) at their fi nal assessment. These results are in line 
with the fi ndings shown by Lieb et al. 2010  [ 35 ] . Opioid depend-
ent patients with high scores in psychiatric distress should 
receive specifi c care with integrated treatment for both opioid 
dependence and psychiatric disorder.
 The scores of the standardized patient questionnaire SF-36 
measuring the quality of life in terms of general health, emo-
tional and social functioning were relatively low at baseline but 
increased signifi cantly during treatment with buprenorphine-
naloxone for all scales. At baseline no diff erence between compl-
eters and non-completers was found, but at the fi nal assessment 
completers had signifi cantly higher scores and non-completers 
revealed no substantial improvement during treatment. These 
fi ndings suggest that the treatment with buprenorphine-
naloxone improves the patient’s perception of his emotional and 
social condition and his ability to reintegrate into a functioning 
social life. Since non-completers obviously did not benefi t in this 
domain there might be other infl uencing factors, such as dosing, 
withdrawal and psychiatric comorbidity that need to be explored 
in order to support special patient groups in the treatment with 
buprenorphine-naloxone at an early stage.
 The results are in line with an Italian longitudinal outpatient 
survey, which compared the treatment of opioid dependence 
with buprenorphine-naloxone and methadone  [ 32 ] . The reten-
tion rate was similar in both groups but signifi cant improve-
ments of social life, educational level and concomitant drug use 
were found in patients treated with buprenorphine-naloxone.
 The non-interventional study with buprenorphine-naloxone 
provides a unique database with comprehensive, reliable and 
valid data on opioid drug dependence treatment with buprenor-
phine-naloxone in routine care. However the major limitation is 
the strict observational nature of the study and the lack of a con-
trol group. Confounding factors, which may occur during a non-  Ta
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interventional study, cannot be controlled in contrast to clinical 
trials with exact regulations and complete treatment protocol. 
Thus these uncontrolled confounding factors may infl uence 
treatment outcomes. All measures used in this paper were of 
descriptive quality; eff ects and correlations need to be inter-
preted with caution. Since this observational study was part of 
the Risk-Management-Plan and based on a commitment to the 
European Medicine Agency (EMA) after market authorization of 
the product buprenorphine-naloxone, no control group was 
planned and necessary. Nevertheless this database with its 
broad range of variables, standardized assessments and param-
eters describing the course and outcome of the treatment with 
buprenorphine-naloxone from the physician’s and the patient’s 
perspective allows detailed analyses on safety, somatic and psy-
chiatric health as well as subjective and objective eff ects in refer-
ence to special patient groups at diff erent time points. This is the 
main advantage of this non-interventional study in routine care.
 In summary, the results indicate high acceptance and tolerance 
of the treatment accompanied by signifi cant improvements in 
psychiatric, somatic and social functioning. According to these 
data buprenorphine-naloxone has an excellent safety profi le 
also in comparison to methadone with a low risk especially for 
serious intoxications  [ 9 ] . There are increasing safety concerns 
for intoxications with opioid prescription drugs, with no corre-
sponding European data. Data from surveillance studies like this 
may help to better estimate the safety risk associated with the 
use of opioid maintenance treatment.
 Although only pre-treated patients were the target study popu-
lation some physicians included a small group of untreated 
patients and they provided encouraging results. The treatment 
with buprenorphine-naloxone was highly successful for patients 
without any experience in maintenance treatment with direct 
transfer from street heroin use to buprenorphine-naloxone 
treatment.
 The characteristics of non-completers need to be analysed fur-
ther to identify those at risk for negative outcome. Analyses 
should focus on identifying ways to retain such patients in treat-
ment and heighten their chances for treatment success.
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Summary
Background: Clinical studies report the highest risk of dropout in the first few weeks of opioid dependence treatment. 
This secondary analysis of data from a non-interventional study with buprenorphine-naloxone (BNX) aims to evaluate 
the predictive value of the treatment outcomes after the first four weeks in routine care. Methods: Data collected from 69 
sites in Germany, came from a multicentre 12-month study involving 337 opioid-dependent patients.
Results: Patients with negative urine screenings for opiates, cocaine or benzodiazepines at screening, a maximum daily 
dose of 8mg BNX during the first four weeks, significantly lower Global Severity Index (GSI) on the SCL-90-R at day 
0 and again at week 4, had a significantly higher chance of being retained in treatment. The patients who switched from 
d/l-methadone, levo-methadone, buprenorphine or active heroin use showed differences in almost all the parameters that 
were evaluated. Conclusion: The first four weeks of treatment with BNX have a high predictive value for the treatment 
outcome, especially in terms of urine screening, dosing of BNX and psychiatric distress. But the physician in charge needs 
to determine if the patient has been pre-treated with d/l-methadone, levo-methadone or buprenorphine, or whether the 
patient is inducted to BNX directly from heroin, because most of the predictive values seem to be unique for a subgroup 
of patients only.
Key Words: buprenorphine-naloxone, opioid dependence treatment, predictors of treatment outcome, first weeks of 
treatment
1. Introduction
Drug dependence therapy with maintenance 
drugs is an established method for the reduction of 
criminal behaviour and somatic disorders, including 
infectious diseases and drug-related deaths, while 
improving the somatic, mental and social well-being 
of drug-dependent users [10, 21, 26, 27,28, 32,]. The 
first goal of maintenance treatment is to stabilize the 
patient with an adequate dose of the maintenance 
drug, to prevent withdrawal symptoms, and risky and 
health-damaging behaviour. An improved status of 
this kind will give a drug-dependent patient an op-
portunity to regain control over his/her life [8, 10]. 
The first four weeks of treatment seem to be 
extremely important for the general course of opioid 
dependence treatment. Some clinical studies report 
the highest risk of dropout and relapse in the first 
week of opioid dependence treatment [20, 30]. But 
the longer a patient stays in maintenance treatment, 
the higher the chances are of accomplishing positive 
treatment outcomes, including complete abstinence 
from illicit drug use [11, 23, 24, 30]. To keep the pa-
tient in treatment is one of the major challenges of 
maintenance therapy [6], and is influenced by many 
factors. Adequate dosing seems to play a major role. 
Buprenorphine doses of 8 mg/day or less resulted 
in lower retention rates [12] and higher numbers 
of positive opioid urine screenings [3]; by contrast, 
higher doses (12-16mg) resulted in higher chances of 
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achieving complete abstinence from opioid drug use 
[7, 18, 19, 22,]. Thus, an adequate dose of buprenor-
phine-naloxone is a crucial factor in keeping drug-
dependent patients in treatment.
Other predictive variables for high retention and 
positive treatment outcomes are being older, having 
a job, having a history of treatment, being cocaine-
free at baseline [1, 4, 15, 23, 24, 30], and having co-
caine- and heroin-free urine screenings in the first few 
weeks of treatment [9]. Predictors of negative treat-
ment outcomes include cocaine use and polydrug use 
at baseline and during treatment [6, 9, 20, 25, 30]. 
Opioid-dependent drug users show extreme 
heterogeneity in many of their characteristics [32]. 
In any case, it can be assumed that, especially in the 
early phases of treatment, certain characteristics and 
variables are unique to each patient, and can be used 
as reliable signals of a positive or negative course 
and outcome of opioid dependence treatment. These 
signals, if recognized at an early stage of treatment, 
could be used to sdjust the treatment plan, and help 
the patient to be retained and/or reach the ultimate 
objective of complete abstinence.
Despite several clinical trials with tight assess-
ment schedules for the early weeks of treatment [14, 
16, 31], there have been no published multisite, long-
term, observational, non-interventional studies in rou-
tine care that provide a detailed description of the first 
four weeks of treatment with buprenorphine-naloxone 
(BNX), and allow an assessment of the reliability of 
predictors for positive treatment outcome. Only one 
single-site, observational cohort study by Stein et al. 
[30] described the results of 41 opioid-dependent pa-
tients treated with buprenorphine-naloxone, with a 
follow-up of 6 months; their results on retention and 
its predictive factors reflected those found in clinical 
trials [30].
This secondary analysis of data from a nation-
wide, non-interventional, observational study with 
buprenorphine-naloxone in routine care [2] aims to 
evaluate the predictive value of the first four weeks 
for the treatment outcomes. 
2. Methods
A detailed description of the study design, goals, 
population, assessment and measures has been given 
in Apelt et al. [2].
2.1. Design of the study
The study, conducted from 2008 to 2010, was 
a nationwide multicentre 12-month prospective, non-
interventional, post-marketing safety study with 12 
assessment points involving 384 opioid-dependent 
patients from 69 general practitioners, clinics and 
outpatient clinics in Germany. Opioid-dependent 
patients over 15 years of age with written informed 
consent and for whom the switch to buprenorphine-
naloxone (BNX) was indicated and planned were 
eligible for selection. Therapeutic indications and 
contraindications of the Summary of Product Charac-
terization (SmPC) for BNX had to be considered. The 
physician had full responsibility for deciding which 
patients should be enrolled, how the treatment with 
BNX was to be implemented and which BNX dos-
age should be applied. Altogether, 337 data sets were 
eligible for analysis. A detailed description of the 
methods used in the study and which datasets were 
excluded from the final analysis is given in Apelt et 
al [2].
2.2. Assessment within the first four weeks
The assessment was performed at day 0 before 
induction into, or a switch to BNX, at days 1, 2, 3, 5 
and 7, and at the end of weeks 2 and 4 of treatment 
with BNX. An extensive clinical research form, com-
pleted by the treating physician, and four standardized 
questionnaires completed by the patients, were used 
to obtain comprehensive data on sociodemographics, 
substance use and addiction history, treatment history, 
comorbidities, co-medication, concomitant drug use, 
urine drug screening, reason for switching to BNX, 
details of BNX treatment, premature discontinuation 
before end of observation, effectiveness, withdrawal, 
craving, quality of life and safety.
The physician’s questionnaire specially devel-
oped for the non-interventional study comprised eval-
uation tools to cover the sections mentioned above, 
including standardized instruments such as a modi-
fied version of the Clinical Global Impression scale 
(CGI) and the Objective Opiate Withdrawal Scale 
(OOWS) [17]. The patients’ questionnaires were the 
Short Form 36 – Health Survey (SF-36) [5], the Sub-
jective Opiate Withdrawal Scale (SOWS) [17], the 
revised psychiatric Symptom Checklist (SCL-90R) 
[13] and, specially invented for the studyvisual ana-
logue scales for craving [2].
2.3. Aims
The general aim of this evaluation was to find 
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predictors for treatment outcomes. The predictors 
specially selected for treatment outcomes were:
• Screening phase (day 0): Gender, age, dose of 
prior maintenance drug for pre-treated patients, 
drug screening results, withdrawal and craving, 
psychiatric status, health-related quality of life.
• Induction phase (days 1 to 7): Withdrawal and 
craving, dose of BNX.
• Stabilization phase (weeks 2 to 4): Withdrawal 
and craving, psychiatric status, health-related 
quality of life, dose of BNX.
2.4. Statistics and Analyses
The following groups were selected and will 
now be compared:
2.4.1.Retention Status
• Positive Outcome (PO): Patients still in treat-
ment with BNX at the end of observation 
(month 12) including patients with regular end 
of treatment before end of observation (patient 
abstinent) (n = 195)
• Negative Outcome (NO): Patients with docu-
mented premature discontinuation of the treat-
ment with BNX for any reason other than regu-
lar end of treatment (patient abstinent) before 
end of observation (month 12) (n = 142). Rea-
sons for premature discontinuations were, for 
example: “lost to follow up” (16.7%), “con-
comitant drug use/relapse” (12.2 %), “side ef-
fects” (12.2%) and “non-compliance/discipli-
nary reasons” (10.9%) [2].
2.4.2. Previous Drug:
• MTD: Pre-treated patients switched from d/l-
methadone (n = 51).
• L-MTD: Pre-treated patients switched from 
levo-methadone (n = 24).
• BUP: Pre-treated patients switched from the 
mono buprenorphine product (n = 162).
• HER: Patients with no current maintenance 
treatment inducted BNX directly from heroin 
use (n = 93).
Logistic regressions, analysis of variances or 
chi-square tests were used to analyse correlations be-
tween the defined patient groups and selected predic-
tive parameters. Missing values and “no test” were 
both defined as positive results. The Kaplan-Meier 
method was used to estimate retention rates and 
times. For the determination of group differences in 
retention rates, the log rank test was used. All statis-
tical analyses were performed using STATA/SE 9.0 
[29].
3. Results
3.1.  Patient’s Characteristics
Table 1 summarizes patients’ characteristics at 
day 0. Predictors of the screening phase for positive 
treatment outcome (PO) were: older age, stable rela-
tionship and own flat, or living with family members. 
Patients with PO had a longer drug dependence his-
tory and pre-treated patients had been significantly 
longer in their previous maintenance treatment be-
fore switching to BNX, especially those who had 
previously been BUP patients. Fewer withdrawal 
symptoms and less craving for opiates were further 
predictors forPO. By contrast, patients with negative 
treatment outcome (NO) were more likely to be sin-
gle, homeless, hepatitis C-positive and more severely 
burdened with psychiatric comorbidity. They report-
ed higher rates for craving and withdrawal at day 0.
3.2  Prior maintenance treatment
The prior treatment status (i.e., whether the pa-
tient had been switched from a previous treatment, 
or had been inducted directly from active heroin use) 
had no impact on treatment outcome. Conversely, a 
patient switched from L-MTD had a higher chance 
of being retained in treatment with BNX for the com-
plete 12 months of observation. A higher last dose of 
the prior maintenance drug before switching to BNX 
was a factor predictive for PO in patients switched 
from MTD and L-MTD.
3.3  Urine drug screening
An overall lower total number of positive drug 
screenings at day 0 was predictive for PO (2.6±1.7 
vs. 3.2±1.7 NO, p=.004, OR 0.83, 95%CI 0.72-0.94), 
particularly for opiates (33.3% vs. 45.8%, p=.021), 
cocaine (6.2% vs. 16.2%, p=.003) and benzodi-
azepines (21.0% vs. 35.9%, p=.002). A significant 
difference in the total number of positive drug screen-
ings was only found in L-MTD patients (1.4±1.0 PO 
vs. 4.3±1.9 NO, p<.001, OR 0.23, 95%CI 0.06-0.79).
3.4 Dose of BNX
Patients with NO started with slightly higher 
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doses of BNX on day 1 of treatment. On day 2 the 
average dose increased in both groups. While the 
average dose in patients with PO already started to 
decrease on day 3, in patients with NO the average 
dose was stable until day 7. In week four both groups 
reached almost the same average dose of their day of 
induction. 
 “Clean” patients were excluded from this analy-
Table 1: Patients’ characteristics at baseline. 
Total Sample PO NO
337* 195 142 p
Age in years [mean (SD)] N = 336 35.1±8.8 36.0±9.0 33.9±8.4 .029
Male [n (%)] N = 337 258 (76.6) 154 (79.0) 104 (73.2) .220
Marital status [n (%)] N = 334
- Single 201 (60.2) 108 (56.3) 93 (65.5) .088
- Married/living with a partner 102 (30.6) 69 (35.9) 33 (23.2) .013
- Divorced 30 (9.0) 14 (7.3) 16 (11.3) .209
Occupation [n (%)] N = 337
- Employed 125 (37.1) 75 (38.5) 50 (35.2) .542
- Unemployed 179 (53.1) 100 (51.3) 79 (55.6) .429
Residential status [n (%)] N = 337
- Own flat/house or living with family 296 (87.8) 177 (90.8) 119 (83.8) .053
- Homeless 5 (1.5) 0 (0.0) 5 (3.5) .008
Years of dependence [mean (SD)] N = 311 13.8 (8.7) 14.6 (8.5) 12.8 (8.8) .077
Currently in substitution treatment [mean (SD] N = 337 244 (72.4) 140 (71.8) 104 (73.2) .958
Years of current substitution treatment [mean (SD] 
N = 213 3.8±3.6 4.3±4.0 3.1±3.0 .022
- Buprenorphine 4.2± 3.8 5.0± 4.3 3.0± 2.5 .003
- D/L-Methadone 3.1± 3.1 3.1± 2.8 3.2± 3.6) .931
- Levo-Methadone 3.3± 3.6 2.7± 3.0 5.0± 4.7 .177
Type of current substitution treatment [n (%)] 
- Buprenorphine 162 (66.4) 93 (66.4) 69 (66.4) .989
- D/L-Methadone 51 (20.9) 29 (20.7) 22 (21.2) .933
- Levo-Methadone 24 (9.8) 18 (12.9) 6 (5.8) .066
Dose of prior substitution treatment [mean (SD)] 
- Buprenorphine (N = 161) 7.7± 4.3 7.2± 4.1 8.4± 4.4 .088
- D/L-Methadone (N = 50) 41.8± 37.2 53.6± 42.4 25.6± 20.1 .007
- Levo-Methadone (N = 23) 26.5± 17.1 31.0± 16.2 10.2± 8.6 .013
Hepatitis C infection [n (%)] N = 335 121 (36.1) 62 (31.8) 59 (42.1) .009
HIV infection [n (%)] N = 272 4 (1.2) 2 (1.0) 2 (1.4) .637
Psychiatric comorbidity – physician’s assessment [n 
(%) N = 337 193 (57.3) 106 (54.4) 87 (61.3) .206
Number of psychiatric comorbidities [mean (SD)] 
N = 193 2.0± 1.5 1.9± 1.6 2.1± 1.5 .538
Psychiatric Status – SCL90R [mean (SD)] 
- GSI (N = 316) 0.7± 0.6 0.7± 0.6 0.8± 0.6 .051
- PST (N = 321) 37.0± 24.0 34.3± 24.5 40.5±23.1 .023
- PSDI (N = 318) 1.5± 0.5 1.5± 0.5 1.6± 0.5 .161
Withdrawal [mean (SD)]
- Objective Opiate Withdrawal Scale (N = 337) 8.8± 8.1 8.4± 8.0 9.4± 8.2 .259
- Subjective Opiate Withdrawal Scale (N = 325) 17.2± 13.5 15.9± 13.4 19.0± 13.6 .043
Craving [mean (SD)]
- Total Score (N = 325) 12.4± 11.1 10.2± 9.6 15.4± 12.3 <.001
- Opiate Craving (N = 323) 32.3± 33.2 27.6± 30.9 38.9± 35.4 .003
Quality of Life – SF36 [mean (SD)]
* Eligible datasets
PO = Positive Treatment Outcome; NO = Negative Treatment Outcome
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during the first four weeks of treatment
No significant differences in dosing of BNX 
within the first four weeks were found concerning 
regions of Germany. Since only 3 outpatient clinics 
participated in the study, the type of setting was not 
analysed as a possible influencing factor.
3.5 Withdrawal 
To measure the signs and symptoms of opiate 
withdrawal, the subjective and objective opiate with-
drawal scales (OWS) were used [17]. Lower opiate 
withdrawal predicted positive treatment outcome 
(PO). In the objective scale (OOWS) patients with 
PO received lower scores from day 3 to week 4, and 
in the subjective scale (SOWS) they achieved lower 
scores from day 2 to week 4. There were no differenc-
sis, because their dosing was significantly lower, and 
it also decreased more rapidly during the first four 
weeks; it therefore fails to reflect the expected nor-
mal course of dosing after induction, or switch to 
buprenorphine-naloxone.
Figure 1 shows the average dose of BNX during 
the first four weeks of treatment (N = 323)
If controlled for prior treatment/drug (see Table 
2), there is no difference in dosing between PO and 
NO in patients switched from MTD or HER. Patients 
with PO switched from L-MTD received slightly 
lower doses of BNX on day 1 and considerably high-
er doses at week 4. The switch from BUP to BNX led 
to an average dose increase of 0.5 mg in both groups. 
However, BUP patients with PO received significant-
ly lower doses of BNX. 
Table 2 shows dosing of BNX by previous drug 
Table 1: Patients’ characteristics at baseline. 
Total Sample PO NO
337* 195 142 p
- Physical Health (N = 324) 52.9± 18.6 54.3± 18.3 51.0± 18.9 .118
- Mental Health (N = 320) 50.8± 24.2 52.0± 25.1 49.0± 22.9 .277
Positive Urine Drug Screening [n (%)] 
- Opiates (N = 331) 124 (37.5) 60 (31.6) 64 (45,4) .010
- Cocaine (N = 330) 28 (8.5) 6 (3.2) 22 (15.6) <.001
- Cannabis (N = 252) 83 (32.9) 45 (31.5) 38 (34.9) .570
- Benzodiazepines (N = 330) 85 (25.8) 37 (19.4) 48 (34.5) .002
General Health – physician’s assessment mean (SD)] 
N = 335 1.7± 1.0 1.7± 1.0 1.8± 1.0 .384
* Eligible datasets
PO = Positive Treatment Outcome; NO = Negative Treatment Outcome
Figure 1. Average dose of BNX during the first four weeks of treatment (N = 323).
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By week 4, however, the difference was no longer 
significant compared with BUP patients with NO. 
The same pattern can be found in the scores from the 
self-assessment questionnaire SOWS for this group. 
Prior HER users with PO achieved significantly lower 
scores for opiate withdrawal between day 7 and week 
4 of BNX treatment, but only on the subjective scale. 
According to physicians, neither group of HER us-
ers differed in terms of opiate withdrawal at screen-
ing and during the first four weeks of treatment with 
es in withdrawal symptoms between the two groups 
in prior MTD patients. Prior L-MTD patients with 
PO showed significantly fewer objective withdrawal 
symptoms from day 3 to week 4. A similar pattern 
is found in the SOWS, with significantly lower with-
drawal symptoms for patients with PO as early as day 
2 of BNX treatment. According to the ratings given 
by the treating physicians, prior BUP patients with 
PO showed significantly fewer opiate withdrawal 
symptoms in the first two weeks of BNX treatment. 
Table 2: Dosing of BNX by previous maintenance treatment and previous drug, during the first four weeks of 
the study
MTD (n = 51) L-MTD (n = 24) BUP (n = 162) HER (n = 93)
PO NO p PO NO p PO NO p PO NO p
Day 1 12.8 12.5 .793 8.2 11.0 .124 7.7 8.9 .066 9.2 8.7 .641
Day 2 13.3 12.8 .793 11.5 12.0 .857 7.8 9.3 .021 9.7 9.5 .855
Day 3 11.9 12.4 .724 12.4 12.0 .900 7.9 9.6 .021 9.6 9.6 .995
Day5 11.4 11.4 .960 12.1 12.0 .964 8.0 9.6 .028 9.4 9.7 .797
Day 7 10.8 10.6 .894 12.1 12.0 .964 7.9 9.9 .008 8.9 9.7 .440
Week 2 11.0 10.3 .450 11.9 10.7 .607 8.0 9.4 .070 8.5 9.7 .199
Week 4 10.6 10.3 .805 12.0 7.5 .083 7.9 9.3 .057 8.3 9.6 .226
MTD: Patients switched from d/l-methadone
L-MTD: Patients switched from levo-methadone
BUP: Patients switched from the mono-compound buprenorphine
HER: Patients inducted directly from heroin use
PO = Positive Treatment Outcome NO = Negative Treatment Outcome
Figure 2. Craving for opiates by previous substance
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BNX.
3.6 Craving for Opiates
Craving was measured with the self-assessment 
100 mm visual analogue scales for 12 substances [2]. 
Lower craving for opiates predicted PO in all three 
phases of the first four weeks of treatment with BNX. 
As shown in Figure 2, the significant difference be-
tween PO and NO is only found in patients previously 
treated with L-MTD or BUP. At screening and in the 
first two days of treatment with BNX, patients with 
PO previously treated with MTD experienced higher 
craving for opiates, but at the end of week 4 these 
patients experienced marginally lower craving. No 
differences in terms of craving were found in prior 
HER users.
3.7  Psychiatric Distress (SCL-90-R)
The psychiatric distress status was measured 
with the standardized self-assessment tool SCL-
90-R. The Global Severity Index (GSI) is the best 
indicator for the current extent of overall psychiat-
ric distress [13]. A lower value for this global scale 
at screening (0.7±0.7 vs. 0.8±0.6 NO, p=.051) and 
week 4 (0.3±0.4 vs. 0.4±0.5, p=.030) predicted PO. 
The most severe forms of psychiatric distress were 
measured in L-MTD patients at screening for both 
groups (1.1±0.5 PO vs. 0.9±0.3 NO, p=.609) and at 
week 4 for patients with NO (0.3±0.3 vs. 0.6±0.4, 
p=.098). The mildest psychiatric distress was meas-
ured in BUP patients at screening for both groups 
(0.5±0.5 vs. 0.7±0.5, p=.004). MTD patients did not 
differ at screening or at week 4. At screening, prior 
HER users received scores that were similar to those 
of patients previously on MTD, with no differences 
between PO and NO, but at week 4 prior HER users 
with PO reported significantly milder psychiatric dis-
tress (0.3±0.3 vs. 0.5±0.5, p=.025). 
3.8  Health-related Quality of Life (SF-36)
The health-related quality of life (QoL) was 
evaluated with the self-assessment tool SF-36, which 
measures the subjective core indicators of physical 
and mental health [5]. No predictive value was found 
in the two global scales, physical and mental health. 
In any case, patients with positive treatment outcome 
(PO) achieved slightly higher scores in both global 
scales at screening (physical health: 54.3±18.3 PO vs. 
51.0±18.9 NO, p=.118; mental health: 52.0±25.1 vs. 
Figure 3. Kaplan-Meier Survival Curves by previous Drug
- 94 -
Heroin Addiction and Related Clinical Problems 16(3): 87-98
ferences in survival and treatment duration between 
the four previous drug groups.
Patients with a maximum dose of ≤8 mg per 
day BNX during the first four weeks stayed signifi-
cantly longer in treatment compared with patients 
with at least one dose of >8 mg per day during the 
first 4 weeks (Log-rank: χ2 = 3.78, p=.052; two-
sample t-test: mean retention 282.0±136.6 days vs. 
241.1±149.2 days, t = 2.57, p=.011).
Patients showing no cocaine use at screening 
stayed significantly longer in treatment than those 
with positive urine screening for any illicit drug 
(log-rank χ2 = 7.06, p=.008). Patients with negative 
urine screenings for opiates, cocaine and/or benzodi-
azepines had a significantly longer treatment duration 
than those with positive test results for all three sub-
stances (Log-rank χ2 = 5.08, p=.024). 
 
4. Discussion
The results of this study proved that opioid-de-
pendent drug users are, indeed, an extremely het-
erogeneous group [32]. Most of the characteristics 
evaluated at baseline and during the first four weeks 
of treatment with buprenorphine-naloxone (BNX) are 
specific for certain patient groups, especially con-
cerning prior substance and treatment experience. 
Despite all the individual differences, this evaluation 
found parameters that can be reliably used as signals 
to adjust the treatment plan, and influence course and 
outcome of opioid dependence treatment with BNX.
The major challenge in drug-substitution treat-
ment is to retain patients in treatment [6] and thus 
enable them to regain control over their lives [8, 10]. 
The overall 4-week retention rate was 89.3%, irre-
spective of whether the patient was switched from an 
ongoing maintenance treatment, or inducted directly 
from heroin use (HER). As found in previous studies, 
being older, treatment experienced, and showing no 
cocaine use at screening predicted higher chances of 
retention [1, 4, 15, 23, 24, 30]. In this study, employ-
ment status at screening had no significant impact on 
retention, but patients who had their own flat, or were 
still living at home with their family, seemed to ben-
efit from a more stable living condition. By contrast, 
homeless patients had practically no chance of a posi-
tive treatment outcome.
In previous studies, polydrug use predicted low 
retention and a high chance of dropout [6, 9, 20, 25, 
30]. In this study this criterion only applied to pa-
tients switched from levo-methadone (L-MTD). Sin-
gle negative test results for benzodiazepines, cocaine 
49.0±22.9, p=.277) and at week 4 (physical health: 
62.9±13.3 vs. 60.1±14.7, p=.112; mental health: 
65.6±20.0 vs. 61.8±20.9, p=.142). No differences 
at screening or in week 4 were found in patients 
switched from MTD, L-MTD or HER at screening, or 
at the end of week 4. But previous BUP patients with 
PO achieved significantly higher scores at screening 
(physical health: 62.8±14.4 vs. 54.8±17.6, p=.002; 
mental health: 64.6±21.7 vs. 53.8±23.7, p=.003). By 
week 4 the scores were no longer significant (physi-
cal health: 66.4±13.4 vs. 62.2±15.1, p=.093; mental 
health: 71.3±20.0 vs. 65.2±21.8, p=.098). 
As itemized within the nine single scales, higher 
scores in the scales for “physical role functioning” 
at week 4 (7.2±1.3 PO vs. 6.8±1.5 NO, p=.046), and 
for “pain” at screening (9.1±2.9 vs. 8.1±3.3, p=003) 
and week 4 (10.6±1.8 vs. 9.9±5.5, p=.010) predicted 
a positive treatment outcome (PO). 
The extent of improvement between baseline 
and week 4 was only predictive for L-MTD patients, 
but, conversely, neither for the total population nor 
for MTD, BUP or HER. L-MTD patients with PO 
achieved higher improvement scores in both global 
scales (physical health: improvement 23.1±11.8 PO 
vs. 4.3±6.5 NO, p=.008; mental health: improve-
ment 40.2±20.8 vs. 10.8±9.7, p=.015) and again in 
the single scales for “physical functioning” (4.2±3.0 
vs. 0.3±2.1, p=.024), “pain” (3.2±1.7 vs. -0.5±1.9, 
p=.001), “social functioning” (2.3±1.5 vs. -0.5±1.3, 
p=.004) and “emotional well-being” (7.4±4.6 vs. 
7.8±2.6, p=.033). For BUP patients the only predic-
tive value for PO was found in the scale for “drug 
dependence” (2.2±6.9 vs. 4.9±8.7, p=.049).
3.9  Retention and dropout
The 4-weeks survival probability for the total 
population was 89.3%. One quarter (25.4%) of all 
patients with negative treatment outcome (NO) (n = 
142) prematurely terminated treatment with BNX in 
the first four weeks, including 9 of the group during 
the first week.
Figure 3 shows the survival probability by pre-
vious drug. The highest retention and lowest dropout 
rate in the first four weeks was found in prior MTD 
patients (13.6%). 24.6% of patients with NO in prior 
BUP patients and 23.7% of HER users dropped out 
of treatment during the first four weeks. Of prior L-
MTD patients, 2 out of 6 patients with NO terminated 
their treatment prematurely during the first 4 weeks. 
Log-rank test and logistic regression revealed no dif-
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characteristics, their best possible treatment setting.
The predictive value of some of the variables 
only applied to patients switched from L-MTD, 
whereas for MTD patients almost none of the vari-
ables could be used as predictors at this early stage 
of BNX treatment. In addition, prior MTD patients 
and HER users did not differ in their characteristics at 
baseline, but HER users seemed to draw considerably 
more benefit from the BNX treatment than MTD pa-
tients. These findings support the suitability of BNX 
as a first-line medication for active heroin users.
One of the limitations of the study might be the 
absence of a control group. Since the study did not 
examine the efficacy of BNX, but aimed to evaluate 
the safety and effectiveness of the switch from an on-
going maintenance treatment to BNX in routine care, 
this limitation is acceptable. Another limitation is the 
disproportionate distribution of patients to the prior 
treatment/drug group. The high predictive value for 
L-MTD patients might be due to their low number of 
only 24 patients. Future studies should be conducted 
with a higher, more evenly distributed number of pa-
tients to evaluate the switch from L-MTD, MTD and 
HER to BNX, and to generate more robust data. An-
other limitation might be the recruiting process: Only 
patients who agreed to participate in the study and 
signed the informed consent form were eligible for 
inclusion in the 12-month observation period. That 
leaves open the possibility of a positive selection bias. 
Patients who refused to participate, as well as those 
who were excluded from consideration as study can-
didates by the participating physician were not evalu-
ated, and no comparison with the group of study par-
ticipants in assessing certain parameters is possible. 
The major strength of the study is its authentic 
reflection of the real life situation in opioid depend-
ence treatment in Germany. It was the sole responsi-
bility of the physician who was in charge to decide 
which patients should be enrolled, how the treatment 
with BNX was to be implemented, and what dose of 
BNX the patients would receive. 
5. Conclusions 
The first four weeks of BNX treatment after a 
switch from d/l-methadone, levo-methadone, bu-
prenorphine or active heroin use have a high value 
in predicting a positive treatment outcome, especially 
with reference to the parameters: withdrawal, craving 
and psychiatric distress, to be measured at the screen-
ing phase (day 0), and at the end of the stabilization 
phase (week 4). These values need to be considered 
or opiates at the screening phase were predictive for 
positive treatment outcomes in patients switched 
from BUP and L-MTD. Previous drug use clearly 
had no impact on retention or on dropout for patients 
switched from d/l-methadone (MTD) or inducted to 
BNX from active heroin use.
Contrary to international findings on a positive 
correlation between higher doses of BNX (12-16mg) 
and high retention [7, 18, 19, 22], in this study a lower 
dose of BNX in the first four weeks (≤8 mg) predict-
ed a higher level of retention. The reason might be 
that patients with a positive treatment outcome (PO) 
had, in general, a more favourable sociodemographic, 
medical and addiction history profile than those with 
a negative outcome (NO). Physicians seem to allocate 
their patients to a certain induction dose in line with 
specific patient characteristics such as social circum-
stances, physical and mental health, withdrawal and 
craving. The high probability of treatment retention 
in patients with a maximum dose of 8 mg per day 
during the first four weeks of treatment with BNX 
might be explained by the fact that these patients start 
their therapy from a more favourable level than those 
who received over 8 mg per day of BNX at least once 
during the first four weeks. At present this largely un-
expected outcome cannot be adequately explained. It 
follows that this surprising finding calls for further 
detailed analysis after taking into account the impact 
of craving, withdrawal, and prior maintenance dose, 
as well as psychiatric distress, quality of life and oth-
er important parameters pertinent to the correlation 
between BNX dose and retention. In addition, in fu-
ture studies the concerns of patients over the effects 
of naloxone in the combination product and the im-
portance of the physician-patient relationship should 
become a focus of attention.
Parameters assessed in the screening phase (day 
0) have a high predictive value and should be studied 
for treatment planning by physicians. Still more im-
portantly, week 4 of the stabilization phase in BNX 
treatment seems to play a major role in measuring 
predictive values for positive treatment outcomes and 
high chances of retention. Differences between pa-
tients with PO and NO were most frequently found 
in this phase. In particular, scores for psychiatric dis-
tress, withdrawal, craving and dosing of BNX differ 
strongly at week 4, and could therefore be used as 
signals for operative improvements to the treatment 
plan. As a result, the physician in charge should test 
these variables by applying standardized patient 
questionnaires at the end of the stabilization phase, so 
as to provide patients, who have rather unfavourable 
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in close conjunction with age, current drug use, social 
status and treatment experience. For optimal treat-
ment redefinition to raise the patient’s chances of 
being retained and of achieving a positive treatment 
outcome, the physician in charge needs to take into 
account whether the patient has been pre-treated with 
d/l-methadone, levo-methadone or buprenorphine, or 
whether the patient was inducted into BNX direct-
ly from heroin. Many predictive values seem to be 
unique to a subgroup of patients only.
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Background: Some case series mention possible liver toxicity in
opioid‐dependent patients under buprenorphine treatment.
Methods: This 12‐month prospective observational follow‐up study
in opioid‐dependent patients under buprenorphine–naloxone treat-
ment assessed outcome and safety issues. At baseline, 337 eligible
datasets were available; 181 patients completed the 12‐month study.
Liver enzymes were tested at baseline and after 12, 24, and 52 weeks’
treatment.
Results: One to two percent of patients showed mostly discrete
elevations of liver enzymes, but no patient met the criteria for drug‐
induced liver injury. No serious liver‐related adverse events occurred,
but two non‐serious cases of liver enzyme increase were recorded. No
patient dropped out of treatment for liver‐related disorders.
Conclusion: This study is in line with some recent studies and
provides further evidence that buprenorphine–naloxone is relatively
safe with respect to liver injury. (Am J Addict 2014;23:563–569)
BACKGROUND
Buprenorphine is an established medication for the
treatment of opioid dependence.1–8 Two forms of buprenor-
phine are available, both as tablets: One that contains only
buprenorphine, and one that combines buprenorphine with the
opioid antagonist naloxone in a 4:1 ratio. The American
Psychiatric Association (APA)2 and World Federation of
Societies of Biological Psychiatry (WFSBP) guidelines6 state
that buprenorphine is a first‐line medication for the treatment of
opioid dependence, among others. One advantage of bupre-
norphine over other opioid agonists may be its relatively low
risk for fatal intoxications.7 Methadone is considered to be safe
with respect to liver toxicity.9
Other safety issues are of relevance, too. Liver safety in
opioid‐dependent patients receiving opioid replacement therapy
is of particular interest and concern because of the high
prevalence of hepatitis C (HCV), which ranges from 64% to
100% in many cohorts.10–15 In addition, many individuals
under opioid replacement therapy are active alcohol drinkers or
even alcohol dependent and thus have an increased risk of liver
damage.16
Drug‐induced liver injury (DILI), a spectrum of clinical
liver diseases ranging from mild biochemical abnormalities to
acute liver failure, is the most frequent reason for the
withdrawal of approved drugs from the market. In clinical
studies of new drugs, the threshold for considering either more
frequent monitoring of blood levels or discontinuing the drug is
set at different levels, that is, twice the upper limit of the normal
(ULN) reference range (2 ULN), 3 ULN, or 5 ULN.17
The three common signs of liver toxicity in clinical trials are as
follows: (1) A doubling (or more) in the incidence of serum
alanine aminotransferase (ALT) elevation >3 ULN; (2) any
incidence of serum ALT elevation >8–10 ULN; (3) any
incidence of serum ALT elevation >3 ULN accompanied by
a serum bilirubin elevation >2 ULN.18 The classification of
DILI is a matter of debate, and an international expert group
has proposed threshold criteria for DILI.18,19
Population pharmacokinetic analyses indicate that clear-
ance is reduced in subjects with elevated ALT or bilirubin.
Therefore, the actions of buprenorphine may be prolonged in
subjects with impaired hepatic function.3,4 Some case reports
have described a possible risk of liver‐related adverse events
with buprenorphine, mainly in patients with HCV.20–23 The
mechanism of injury associated with buprenorphine is unclear
(see livertox.nih.gov), but a disruption of mitochondrial
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respiration has been discussed.20,21 Buprenorphine undergoes
extensive first‐pass hepatic extraction. Most of the elimination
is biliary.
The low doses used and rapid metabolism may account for
the apparent relative lack of hepatotoxicity when buprenor-
phine is used in conventional doses. Because only limited
evidence is available on this issue, we conducted a 12‐month
observational study to assess liver safety in opioid‐dependent
patients treated with buprenorphine–naloxone.
METHODS
In brief, this was a 12‐month non‐interventional study on
retention rate, outcome, and safety issues in patients switched
under real‐life conditions to buprenorphine–naloxone after pre‐
treatment with buprenorphine, methadone, or L‐methadone.
Details are given in Apelt et al.24 A comprehensive paper‐based
case report form was used for data capture. The study was part
of the Risk Management Plan (RMP) for the newly marketed
product buprenorphine–naloxone (Suboxone1) and therefore a
requirement of the European Medicine Agency (EMA). The
study was registered with the National Institute of Health (NIH)
at ClinicalTrials.gov (NCT00723749).
All physicians prescribing buprenorphine–naloxone were
obligated to report to the market authorization holder (MAH)
any adverse event that occurred during routine treatment. The
MAH provided a special form for this purpose that specifically
defined “non‐serious” and “serious” adverse events: Life‐
threatening adverse events, including death itself, were to be
classified as “serious”; all other adverse events, as non‐serious.
The physicians were solely responsible for assessing and
deciding whether or not an adverse event was related to
buprenorphine–naloxone.
Study Population
A total of N¼ 384 opioid‐dependent patients were enrolled
by 69 physicians working in addiction medicine. The parti-
cipating physicians prescribed the medication in its conven-
tional, commercially available form. Therapeutic indications
and contraindications for opioid dependence treatment
according to the Summary of Product Characteristics (SPC)
for buprenorphine–naloxone and national treatment guidelines
had to be followed when selecting patients for participation in
the non‐interventional study. “Non‐interventional” meant that
physicians were free to decide about the clinical management
of their patients, without following any study protocol. A total
of n¼ 47 patient datasets were excluded from the final
analysis; n¼ 337 eligible datasets were included. Details are
given in Apelt et al.24
The study was approved by the ethics committee of the
Ludwig Maximilian University, Munich, Germany.
Assessments
Assessments included a physician and patient questionnaire
and various psychometric scales (see Ref.24). Liver enzymes
were measured at baseline and after 12, 24, and 52 weeks.
Normal values were defined as follows: alkaline phosphatase
(AP) 40–129U/L (males), 35–104U/L (females); glutamic‐
pyruvic transaminase (GPT; also referred to as ALT) 10–50U/
L; glutamate oxaloacetate transaminase (GOT; also referred to
as AST) 10–35U/L; gamma‐glutamyl transpeptidase (GGT)
<66U/L (males),<39U/L (females). All adverse events (non‐
serious and serious, including adverse drug reactions and
pregnancies) were listed, because they were spontaneously
reported and documented at each visit by the treating
physician. No central laboratory was used, and each physician
sent the material to his preferred laboratory. No cytochrome
450 polymorphisms were measured. No data were reported on
consequences in case of changes in liver enzymes, for example,
new medications or testing for viral hepatitis. No treatment
interventions or assessments were defined, since this was a
strictly observational, phase IV study.
DILI was defined according to Abboud and Kaplowitz.18
Statistics
This was a descriptive analysis. Since elevations of liver
enzymes were very rare (see below), no specific subgroup
analysis was performed.
RESULTS
Patients and Outcome
A total of 337 eligible patients were included (258 [76.6%]
male), 181 of whomwere still in treatment after 12months. The
mean age was 35.1 years (8.8); the mean duration of opioid
dependence, 13.8 years (8.7). A total of 121 (36.1%)
participants had a history of HCV infection. The mean
induction dose of buprenorphine was 9.2mg.
All patients were German; ethnicity was not reported.
Baseline patient characteristics are given in Table 1, and details
of enrolment in Figure 1.
A total of 142 patients dropped out before the end of the
observation period. No deaths occurred. Four serious adverse
events (1.2%) were recorded, none of which was a liver
disorder, and 59 non‐serious events (15.9%), three of which
were liver‐associated disorders: One case of HCVinfection and
two cases of increased liver enzymes. In both cases of increased
liver enzymes, treatment was continued, and the treating
physician did not see a correlation with buprenorphine/
naloxone treatment (on the basis of his or her clinical
assumption). No patient dropped out because of a liver
disorder or related adverse event.
Liver Enzymes
Mean values for liver enzymes are given in Figures 2–4.
Detailed results are as follows:
AP: One male (117–135U/L) but no female patient showed
mild elevation at week 12 compared to baseline; two male
patients (83–176 and 123–150U/L) and one female patient
(123–150), at month 6; threemale patients (102–139, 100–146,
110–136U/I), at month 12.
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GPT: Seven male patients (48–61, 37–54, 38–51, 47–52,
31–61, 13–91, 42–88U/I) but no female patient showed mild
elevations at week 12; four male patients (46–51, 22–60, 31–
67, 23–81U/I) and one female patient (19–36U/I), at month 6.
Three male (20–51, 39–96, 38–56U/I) and two female patients
(20–51, 20–85U/I) showed mild to moderate elevations at
month 12.
GOT: Seven male patients (49–51, 32–51, 39–52, 36–58,
22–78, 42–61, 33–54U/I) but no female patient showed mild
to moderate elevations at week 12; three male patients (26–51,
39–57, 35–62U/I) and one female patient (24–38 U/I), at
month 6. Two male patients (41–56, 48–51U/I) but no female
patient showed discrete elevations at month 12.
GGT: Four male patients (57–68, 60–69, 60–75, 61–72U/I)
and one female patient (34–46U/I) showed discrete elevations
at week 12, although these were only just above the upper norm
value limit. Three male (42–82, 16–108, 65–71U/I) and three
female patients (25–74, 28–128, 33–42) showed mild
elevations at week 24; one male patient (37–68U/I) and two
female patients (24–42, 28–69U/I), at week 52.
In conclusion, none of the men or women showed an
elevation of liver enzymes >3 upper limit over baseline
according to the definition of DILI18 used in this study, and
only one women had a >2 elevation compared to baseline.
DISCUSSION AND CONCLUSIONS
This 12‐month observational, non‐interventional study
provided no evidence for a significant risk of liver enzyme
elevation or hepatic failure in opioid‐dependent patients under
treatment with buprenorphine–naloxone. Although 36% of the
participants had a history of HCV, no clinically relevant cases
of drug‐induced liver injury were found in this study.
Elevations in liver enzymes were rare (1–2% of patients),
mostly within or slightly above the upper normal value, and no
patient dropped out of treatment because of a liver‐related
adverse event. This study differs from the few other studies
published so far on this issue in that it was a strictly
observational study on safety aspects of buprenorphine
treatment, while the other studies were primarily designed to
measure liver toxicity25 or were retrospective.26
Concerns about liver toxicity of buprenorphine and the
buprenorphine/naloxone combination were raised by some
clinical reports of liver injury in patients with hepatitis. Petry
et al.26 found in a retrospective study that patients diagnosed
with hepatitis B or C had significant increases in transaminase
levels, while patients without hepatitis did not. In addition,
hepatotoxicity of buprenorphine has been reported in
overdose27 or intravenous misuse.28 There are case reports
of patients with HCV developing acute hepatitis while
misusing their buprenorphine medication i.v.20,21,23 Herve
et al.29 reported on seven cases of acute cytolytic hepatitis due
to buprenorphine. Five out of seven subjects presented with
FIGURE 1. Enrollment and eligible datasets.
TABLE 1. Patient Characteristics at Baseline
Total sample
(N¼ 337)
Age in years [mean (SD)], N¼ 336 35.1 (8.8)
Male [n (%)], N¼ 337 258 (76.6)
German nationality [n (%)], N¼ 336 281 (83.4)
BMI [mean (SD)], N¼ 332 23.8 (3.9)
Marital status [n (%)], N¼ 334
Single 201 (60.2)
Married/living together 102 (30.6)
Divorced 30 (9.0)
Years of dependence [mean (SD)], N¼ 311 13.8 (8.7)
Maintenance treatment [n (%)], N¼ 244
Buprenorphine 162 (66.4)
D/L‐Methadone 51 (20.9)
L‐Methadone 24 (9.8)
Without prior maintenance treatment [n (%)] 49 (16.7)
Hepatitis C infection [n (%)], N¼ 335 121 (36.1)
HIV infection [n (%)], N¼ 272 4 (1.2)
Eligible datasets.
Soyka et al. November–December 2014 565
acute icteric hepatitis without abdominal pain or fever; there
was no evidence for liver failure. Some of the patients
described were reexposed to buprenorphine and some
remained on a lower dose without further evidence of liver
injury. Cytolysis and jaundice resolved rapidly. Bruce and
Altice22 reported a case series of four individuals with acute
HCV infection and abnormal liver transaminases. Patients
tolerated buprenorphine treatment well and showed improve-
ment in their transaminases during buprenorphine treatment.
Despite the small number of reports of buprenorphine
treatment being associated with hepatic injury or dysfunction
in opioid‐dependent patients,30 these case reports nevertheless
led to the recommendation that buprenorphine‐treated patients
be tested formarkers of liver injury at treatment initiation and at
intervals thereafter. As a possible explanation for hepatotoxic-
ity of buprenorphine, a disruption of mitochondrial respiration
via proton donation by buprenorphine was discussed by
Berson et al.,20,21 on the basis of their animal studies.
The issue of possible liver injury by buprenorphine was
more systematically studied in a sample of adolescents
FIGURE 2. Mean GPT values for males (m) and females (f) at T1 (day 0), T2 (week 12), T3 (month 6), and T4 (month 12). The standard deviations
(error bar) are shown as vertical lines, the cut‐off values as horizontal lines.
FIGURE 3. MeanGOT values for males (m) and females (f) at T1 (day 0), T2 (week 12), T3 (month 6), and T4 (month 12). The standard deviations
(error bar) are shown as vertical lines, the cut‐off values as horizontal lines.
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receiving buprenorphine.31 In this study, 152 patients were
randomized to 2‐week detoxification with buprenorphine–
naloxone (detox) or 12 weeks with buprenorphine–naloxone
(bup/nx). In 111 patients, at least one set of transaminases were
measured. In 8 of the 60 bup/nx and 12 of the 51 detox patients,
at least one elevated aspartate aminotransferase (AST) value
was measured. HCV status was significantly associated with
transaminase abnormalities. Taken together, this exploratory
study found no evidence for hepatotoxicity of buprenorphine.
A phase IV hepatic safety study to prove the safety of
long‐term use of buprenorphine compared to standard care
(methadone) was required as part of the FDA approval of
buprenorphine products in 2002. Saxon et al.25 performed a
randomized controlled study of 1,269 opioid‐dependent,
treatment‐seeking patients and followed them for 32 weeks.
The study was performed by the National Institute on Drug
Abuse Trials Network (NIDA) in cooperation with Reckitt
Benckiser Pharmaceuticals. A total of 731 participants met
“evaluable” criteria, defined as completing 24 weeks of
medication and providing at least four blood samples.
Participants were randomized to either buprenorphine or
methadone. Changes in transaminase levels did not differ by
medication condition. Not surprisingly, baseline infection
with hepatitis C or B was the only significant predictor for
elevation of transaminase levels. Nine buprenorphine and 15
methadone patients showed “extreme” liver test elevations
defined as ALTor AST>10ULN, total bilirubin>2mg/dl,
direct bilirubin >2mg/dl, or maximum international nor-
malized ratio >1.5 at any point during the 24 weeks of the
study. These patients were more likely than those without
extreme elevations to have seroconverted to both hepatitis
B and C during study or to have used illicit drugs during
the first 8 weeks of treatment. Not surprisingly, baseline
infection with hepatitis C or B was the only significant
predictor of transaminase levels increasing from low to
elevated.
An important study on the effects of buprenorphine–
naloxone on hepatic status in HIV‐infected opioid‐dependent
patients was performed byVergara‐Rodriguez et al.32 A total of
303 HIV‐infected patients initiating buprenorphine–naloxone
treatment were enrolled. Patients receiving or not receiving the
antiretroviral atazanavir were compared. AST and ALT was
measured (inclusion criterion: Levels of both AST and ALT
<5 ULN). Buprenorphine–naloxone did not produce
measurable hepatic toxicity or pharmacodynamic interaction
with atazanavir.
Very recently, McNicholas et al.30 reported data on liver
status and enzymes from the NIDA‐sponsored MOTHER
study, a double‐blind, double‐dummy, flexible‐dosing study in
175 pregnant women comparing the effects of methadone and
buprenorphine on neonatal outcome.33 ALT, AST, and GGT
levels decreased for all subjects across pregnancy. At all
measurements, HCV‐positive subjects exhibited higher trans-
aminases than HCV‐negative subjects, regardless of medica-
tion. Both HCV‐positive and ‐negative buprenorphine‐
maintained participants exhibited lower GGT levels than the
methadone‐maintained participants (p< 0.05). The authors
concluded that neither methadone nor buprenorphine appear to
have adverse hepatic effects in the treatment of pregnant
opioid‐dependent women.
FIGURE 4. MeanGGT values for males (m) and females (f) at T1 (day 0), T2 (week 12), T3 (month 6), and T4 (month 12). The standard deviations
(error bar) are shown as vertical lines, the cut‐off values as horizontal lines.
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No specific pharmacokinetic studies have been conducted
on buprenorphine in patients with liver disease.34 The activity
or expression of CYP3A4 may be significantly decreased in
patients with liver disease.35,36 Dose adjustments may be
considered. Peyriere et al.28 reported two cases of acute
hepatitis related to i.v. administration of buprenorphine in
HCV‐infected patients. Surprisingly, viral replication disap-
peared after acute hepatitis. Patients should be informed about
the risk of acute hepatitis associated with intravenous misuse of
the drug.
Some limitations of this study must be addressed. First, this
was an observational study and no control group was included.
The study focused primarily on clinical outcome and safety
issues in general, not specifically liver toxicity. Still, the large
number of patients studied, long follow‐up, and low number of
liver enzyme elevations seem to be of clinical relevance.
Second, no histological or ultrasound findings were available
for analysis.
In conclusion, this prospective, non‐interventional study
gives further evidence that buprenorphine treatment appears to
be safe regarding liver injury in opioid‐dependent individuals.
Future studies may focus on high‐risk individuals with a severe
liver disorder, in particular hepatitis C infection, to further
explore the possible benefits and risks of buprenorphine–
naloxone in such patients.
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H. Summary and conclusion 
Chapter F: Primary analysis of  the results from the 12-month nation-wide non-
interventional safety study on the treatment of  opioid dependence with buprenorphine-
naloxone in routine care in Germany 
69 sites in Germany provided reliable data from 337 eligible patients and helped generating a 
unique database with the most compact measure schedule and comprehensive assessment 
tools in medication assisted treatment of  opioid use disorders with buprenorphine-naloxone 
under real-life conditions. Despite the instruction to include only patients from an ongoing 
medication assisted treatment, physicians also involved 49 patients with no ongoing 
maintenance treatment and induced them to buprenorphine-naloxone directly from active 
street heroin use. The evaluation of  induction and course of  treatment with buprenorphine-
naloxone over 12 months provided new insights on dosing and its long-term impact on 
retention rate and treatment success for pretreated and untreated patients in routine care. 
The 12-month retention rate of  patients who switched either from an ongoing medication 
assisted treatment with buprenorphine, methadone or levo-methadone or from active street 
heroin use was 57.1% and in line with previous naturalistic, observational studies. 4.2% of  
the patients were rendered abstinent before end of  the 12-month observation by their treating 
physician. There were no deaths and a very low rate of  adverse events during the 
observational period. These findings demonstrated the overall efficacy and high safety profile 
of  buprenorphine-naloxone in the treatment of  opioid use disorders in routine care and 
confirmed findings from clinical studies.  
In contrast to international clinical studies with recommended daily dosages of  16-24 mg, the 
daily doses of  buprenorphine-naloxone were much lower with on average 9 mg at start of  
treatment and 8 mg at end of  observation. Subjective withdrawal symptoms and craving for 
opioids at start of  treatment determine course and outcome of  the treatment. Patients with 
premature treatment termination for reasons other than being rated abstinent (non-
completers) had higher subjective withdrawal and opioid craving at treatment start than 
patients still in treatment with buprenorphine-naloxone at the end of  the 12-month 
observational period (completers). One of  the reasons could be that the daily dosage of  
buprenorphine-naloxone was too low for those patients. Take-home prescription increased 3-
fold during the 12-month observational period, which was the reason for >10% of  the 
patients for switching to buprenorphine-naloxone. 
The study showed (significant) improvement in all domains during the treatment with 
buprenorphine-naloxone for all analysis groups, except for non-completers, who had no 
sufficient improvement in quality of  life, general health, opioid withdrawal and concomitant 
drug use. Only concerning opioid craving, which was measured with a self-assessment visual 
analog scale at all assessment points, data from non-completers revealed a significant decrease 
between baseline and final assessment. However, craving for opioids and withdrawal 
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symptoms were significantly higher both at baseline and final assessment compared to those 
patients still in treatment with buprenorphine-naloxone at the end of  the 12 months of  
observation (completers). For those patients with premature discontinuation of  treatment for 
reasons other than being abstinent (non-completers), one of  the most important goals of  
medication assisted treatment was not fulfilled: to alleviate craving and withdrawal symptoms. 
Patients who had switched to buprenorphine-naloxone directly from street heroin use seemed 
to have the highest benefit from the treatment not only in subjective measures. Significantly 
more of  these patients discontinued treatment with buprenorphine-naloxone prematurely 
because they were rated as abstinent by their treating physicians. Despite the relatively small 
number of  this group of  patients, these encouraging results allow the conclusion, that 
buprenorphine-naloxone is eligible as first line treatment for opioid use disorders. 
Chapter G: Analysis of  the first four weeks in the treatment of  opioid dependence after 
induction or switch to buprenorphine-naloxone and its predictive value for the treatment 
outcome after 12 months of  observation 
Due to a very tight assessment schedule during the first four weeks (day 0, 1-3, 5, 7, week 2 
and 4) the post-authorization safety study provided comprehensive data for a thorough 
evaluation of  induction and stabilization phase in drug dependence treatment with 
buprenorphine-naloxone. Positive treatment outcome was defined as patients still in treatment 
at the final assessment (month 12) or rated abstinent. Variables predicting high retention rate 
and positive treatment outcome were: stable living conditions, being older, treatment 
experienced, lower withdrawal and craving for opioids, lower concomitant drug use and daily 
dosages of  8 mg or less of  buprenorphine-naloxone during the first four weeks. Negative 
treatment outcome was defined as patients with premature discontinuation before end of  
observation for any reason other than being rated abstinent. Variables predicting low 
retention rate and negative treatment outcome were: unstable living conditions, being 
hepatitis positive, severe psychiatric comorbidity, higher withdrawal and craving for opioids as 
well as daily dosages of  more than 8 mg buprenorphine-naloxone during the first four weeks. 
Quality of  life, assessed with the standardized self-assessment form SF-36, was the only 
measure which showed no difference between patients with positive or negative treatment 
outcome concerning physical and mental health. 
The stabilization phase seems to play an important role in predicting treatment outcome. 
Especially psychiatric distress, withdrawal symptoms, craving for opioids and dose of  
buprenorphine-naloxone should be measured by the treating physician during this phase in 
order to redefine treatment parameters to increase patients’ probability for high retention and 
a positive course of  treatment. In summary, the study found indeed certain parameters that 
can be used as predictive signals for treatment course and outcome. Nevertheless many of  
these values are specific for a subgroup of  patients depending on prior substance and 
treatment experience. 
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Chapter H: Analysis of  the development of  liver enzymes over 12 months of  treatment of  
opioid dependence with buprenorphine-naloxone 
As a consequence of  a high rate of  hepatitis C infections and comorbid alcohol misuse or 
even dependence in opioid dependent patients, liver safety needs to be taken into account 
during medication assisted treatment. Hepatotoxicity of  buprenorphine had been found 
especially in hepatitis C positive patients and when the medication was used in higher dosages 
and/or intravenous. In addition, tests had shown prolonged buprenorphine action when 
certain liver-enzymes were elevated because clearance of  the medication was reduced. The 
post-authorization safety study on drug dependence treatment with buprenorphine-naloxone 
provided comprehensive laboratory data, assessed at baseline, month 3, 6 and 12, allowing in-
depth evaluation of  liver-enzyme value changes over time.  
121 of  the 337 eligible patients (36%) had a history of  hepatitis C infection. There were no 
liver-related serious events and only 3 of  the 59 non-serious adverse events were rated as liver-
associated disorders – one patient because of  a new hepatitis C infection and two patients 
because of  slightly increased liver-enzymes. Treatment with buprenorphine-naloxone was 
continued in all 3 cases. The analysis of  the laboratory parameters revealed no significant risk 
for liver-enzyme elevation, liver injury or failure during the treatment of  opioid dependent 
patients with buprenorphine-naloxone in routine care. The study provided evidence that 
buprenorphine-naloxone is a safe medication when applied as prescribed, even in patients 
with hepatitis C infection. 
Conclusion 
The findings from the 12-month non-interventional post-authorization safety study of  drug 
dependence treatment with buprenorphine-naloxone provided evidence of  its effectiveness 
and safety in routine care treatment settings. Acceptance and tolerance of  buprenorphine-
naloxone was high even among patients switching directly from street heroin use. As with 
other maintenance drugs, the initial response of  patients to the treatment impacts course and 
outcome of  the therapy with buprenorphine-naloxone. Early adjustments of  certain para-
meters could help to retain the patient in the treatment and change the course to a positive 
outcome. 
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I. Summary/Zusammenfassung 
In 2007 buprenorphine-naloxone, a medication for the treatment of  opioid use disorder, was 
launched in Germany. The medication consists of  the combination of  buprenorphine and 
naloxone in a 4:1 ratio and was developed because the mono-compound buprenorphine, a 
well-established medication in opioid dependence therapy, had been subject to diversion and 
misuse. A non-interventional post-authorization safety study was conducted from 2008 to 
2010 to collect comprehensive real-life data on the treatment of  opioid dependent patients 
with buprenorphine-naloxone in Germany. Three major articles, published in international 
peer-review journals, evaluated data from this study on safety, effectiveness and tolerance, 
predictive value of  the first four weeks as well as risk of  liver-enzyme elevation in the 
treatment of  opioid dependent patients with buprenorphine-naloxone. 
The findings from these extensive evaluations indicate a high safety profile, a high effective-
ness, tolerance and acceptability with substantial improvements in quality of  life, mental and 
physical health. There was no evidence for an increased risk for liver-enzyme elevation even 
in patients with hepatitis C infections. In the first four weeks specific and general parameters 
with high predictive value were found that can be used as early signals to adjust the therapy 
plan in order to positively influence course and outcome of  opioid dependence treatment 
with buprenorphine-naloxone in routine care. 
2007 wurde Buprenorphin-Naloxon, ein Medikament für die Behandlung der Opioidab-
hängigkeit, in Deutschland zugelassen. Das Medikament enthält die Kombination von 
Buprenorphin und Naloxon in einem Verhältnis von 4:1 und wurde aufgrund zunehmenden 
Missbrauchs von Buprenorphin, einem gut etablierten Medikament zur Behandlung der 
Opioidabhängigkeit, entwickelt. Eine nicht-interventionelle Sicherheitsstudie wurde von 2008 
bis 2010 durchgeführt, um umfassende Daten zur Routinebehandlung von opioidabhängigen 
Patienten mit Buprenorphin-Naloxon in Deutschland zu erheben. Drei Hauptartikel, die in 
internationalen Peer-Review Fachzeitschriften publiziert wurden, analysierten die Daten der 
Studie hinsichtlich Sicherheit, Effektivität und Toleranz, vorhersagefähiger Variablen der 
ersten vier Wochen sowie das Risiko für erhöhte Leberenzymwerte in der Behandlung von 
opioidabhängigen Patienten mit Buprenorphin-Naloxon. 
Die Ergebnisse dieser umfangreichen Analysen weisen auf  ein hohes Sicherheitsprofil, eine 
hohe Effektivität, Toleranz und Akzeptanz mit deutlichen Verbesserungen in der 
Lebensqualität sowie der psychischen und physischen Gesundheit hin. Es zeigten sich keine 
Anzeichen eines erhöhten Risikos für einen Anstieg der Leberenzymwerte sogar bei Patienten 
mit einer Hepatitis C Infektion. Die ersten vier Wochen haben einen hohen Vorhersagewert 
mit spezifischen und generellen Parametern, die als frühzeitige Signale genutzt werden 
können, um den Behandlungsplan anzupassen und damit Verlauf  und Ausgang der Behand-
lung mit Buprenorphin-Naloxon in der Routinebehandlung positiv zu beeinflussen. 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